The regulation of Rab5 by Phosphatidylinositol 3'-Kinase by Detillieux, Dielle
  
THE REGULATION OF RAB5 BY PHOSPHATIDYLINOSITOL 3′-KINASE 
 
 
 
 
 
 
A Thesis Submitted to the College of Graduate Studies and Research 
 in Partial Fulfillment of the Requirements of the Degree of  
Master of Science  
in the Department of Biochemistry  
University of Saskatchewan  
Saskatoon 
 
 
 
 
 
by 
Dielle Detillieux 
 
 
© Copyright Dielle Detillieux, December 2012. All rights reserved. 
i 
 
PERMISSION TO USE 
 In presenting this thesis in partial fulfillment of the requirements for a Postgraduate 
degree from the University of Saskatchewan, I agree that the Libraries of this University may 
make it freely available for inspection. I further agree that permission for copying of this 
thesis in any manner, in whole or in part, for scholarly purposes may be granted by the 
professor or professors who supervised my thesis work or, in their absence, by the Head of the 
Department or the Dean of the College under which this thesis work was done. It is 
understood that any copying or publication or use of this thesis or parts thereof for financial 
gain shall not be allowed without my written permission. It is also understood that due 
recognition shall be given to me and to the University of Saskatchewan in any scholarly use 
which may be made of any material in my thesis.  
 
 Request for permission to copy or to make other use of materials in this thesis in 
whole or in part should be addressed to:  
 
Dr. Deborah H. Anderson 
Saskatchewan Cancer Agency Cancer Research Unit 
20 Campus Drive 
University of Saskatchewan 
Saskatoon, SK 
S7N 4H4 
ii 
 
ABSTRACT 
Rab5 (Ras-related in brain) and Rab4 are small monomeric GTPases that mediate the 
intracellular trafficking of endocytosed growth factor receptors. Active Rab5-GTP has low 
intrinsic GTP hydrolysis activity that is stimulated by GTPase activating proteins (GAPs) to 
make inactive Rab5-GDP. GAPs provide both a catalytic arginine and switch region 
stabilization functions. The p85 regulatory subunit of phosphatidylinositol 3′-kinase (PI3K) 
has GAP activity towards Rab5 and Rab4, which is not seen in other PI3Ks. The arginine 
“finger” residue within p85 is R274. It is unlikely that p85 stabilizes the switch regions of 
Rab5, which undergo large conformational changes between activation states, because it 
interacts with both Rab5-GTP and Rab5-GDP. In contrast, the PI3K catalytic subunit p110β 
binds only Rab5-GTP, suggesting it interacts with the switch regions. Thus, the GAP 
functions may be provided to Rab5 by the subunits of PI3K acting together, where p85 
provides the arginine finger and p110β stabilizes the switch regions. The binding interface of 
Rab5:p85 was sought using mutations of Rab5 residues not present in the switch regions 
which were conserved in p85-binding Rab proteins (S84, E106, N113, F145, E172, M175, 
K179, K180) in GST pull-down experiments with FLAG-p85. The p85 binding site was not 
resolved with these experiments, suggesting that p85 interaction may involve the contribution 
of multiple residues of the Rab5 protein. The p110β interaction site on Rab5 was investigated 
using Rab5 switch region mutants. Pull-down experiments using a stabilized p110 protein 
construct, where the p85-iSH2 domain was fused to p110 (alpha or beta), were performed. 
Rab5 mutants I53A, F57A, W74A, Q79L, E80R, Y82A, H83E, L85A, M88A, Y89A and 
R91E showed reduced p110β binding. All of these residues except E80 and H83 are involved 
in binding other Rab5 effectors. The Rab5 binding site on p110β was also resolved through 
mutation of p110β in its Ras binding domain, and includes residues I234, E238 and Y244. 
This generation of non-binding mutants of both Rab5 and p110β will be invaluable in the 
characterization of the importance of the p110β:Rab5-GTP interaction for receptor trafficking 
to endosomes in mammalian cells.   
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1.0 INTRODUCTION 
1.1 Overview of signal transduction pathways  
 Cell growth and proliferation within an organism is regulated in part by extracellular 
cues. Growth factor receptors interact with extracellular ligands to transmit signals that cascade 
through protein effectors resulting in cell growth and differentiation (Lemmon and 
Schlessinger, 2010; Heldin and Westermark, 1999). These signals must be turned off in a timely 
manner which is achieved by deactivating the receptor. Some transformed cells exhibit 
increased cell proliferation and survival through the actions of enhanced or sustained growth 
factor signaling pathways (Fleming et al., 1992; Liu and Tsao, 1993; Takeuchi and Ito, 2011). 
These signaling pathways include the Ras/Mitogen Activated Protein Kinase (MAPK) and 
Phosphatidylinositol 3′-kinase (PI3K)/Akt cascades which are activated by receptor tyrosine 
kinases (RTKs) such as the epidermal growth factor receptor (EGFR) and the platelet-derived 
growth factor receptor (PDGFR) (Bartholomeusz and Ganzalez-Angulo, 2012; Jechlinger et al., 
2006) (see Figure 1.1). Amplification of the growth factor receptor HER2 (also known as 
EGFR2) gene, for example, is found in 20%-30% of early stage breast cancers, and leads to 
increased activation of the PI3K/Akt and Ras/MAPK pathways (Hurvitz et al., 2012). The 
regulation of growth factor receptor tyrosine kinase signaling attenuation and degradation is a 
major area of cancer research.  
1.2 Receptor tyrosine kinase signaling 
 Growth factor signaling begins at the receptor level. As mentioned, an extracellular 
ligand such as epidermal growth factor (EGF) interacts with its RTK, e.g. EGFR, which causes 
the receptor to change its conformation, dimerize and phosphorylate tyrosine residues of the 
cytoplasmic domain in trans via its tyrosine kinase domain (Lemmon and Schlessinger, 2010; 
Figure 1.1). These phosphorylated tyrosine residues (pY) recruit proteins with either a Src 
homology 2 (SH2) or a phosphotyrosine binding (PTB) domain, both of which have a high 
affinity for pY in specific amino acid motifs (e.g. the SH2 domain of p85 recognizes pY-x-x-M; 
where x indicates any amino acid) (Felder et al., 1993; Mellor et al., 2012). Truncation of the 
cytoplasmic domain of EGFR, and thus removal of the pY residues, inhibits downstream 
signaling by lack of recruitment and disrupts receptor endocytosis (Barbieri et al., 2000).  
Figure 1.1 Receptor tyrosine kinase signaling pathways. Receptor tyrosine kinases (red) such as 
EGFR and PDGFR interact with an extracellular peptide ligand (blue diamonds) EGF or PDGF, 
respectively, which induces receptor dimerization and phosphorylation of  tyrosine residues in its 
cytoplasmic domain. These phosphorylated tyrosines (pY) recruit SH2-containing proteins to the 
plasma membrane such as p85 (blue) and Grb2 (green). p85 binding to pY alleviates its inhibition 
on p110 which then phosphorylates PtdIns-4,5-bisphosphate to PtdIns-3,4,5-trisphosphate, 
activating the PI3K/Akt signalling axis (blue) which results in cell survival by inactivation of pro-
apoptotic proteins BAD and p53, cell cycle progression, cell growth and protein translation. Grb2 
recruits SOS (orange) which is a GEF to Ras. Active Ras induces the Ras/MAPK signaling 
pathway (purple) which results in transcription,  cell growth, cell survival and cell cycle 
progression through the actions of proteins and transcription factors  pictured, which are discussed 
in detail in the text. Dashed lines indicate indirect regulation between proteins. 
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Normally, the pY-binding SH2-containing proteins transmit signals within the cell by activating 
or recruiting other protein “effectors”, or proteins that act to alter cellular functions such as 
metabolism and transcription, in response to growth factor binding. Two major pathways 
activated by RTKs will be discussed in greater detail below: the Ras/MAPK pathway and the 
PI3K/Akt pathway. 
1.2.1 Ras/MAPK signaling  
 Arguably the most well studied RTK signaling cascade is the Ras/MAPK pathway. The 
incidence of somatic mutation of ras genes, especially K-ras, in all human tumors is as high as 
30% (Fernández-Medarde and Santos, 2011). Activation of this pathway, by RTK signaling or 
by gain of function mutation of downstream proteins, results in cell cycle progression, cell 
survival and increased gene expression by transcription factors. One example of a common gain 
of function mutation in human cancers is in the B-RAF gene, which increases cell growth and 
survival through MAPK1/2, (which is also called extracellular signal related kinase [ERK] 1/2). 
Such mutations also decrease the efficacy of therapeutic inhibitors targeting upstream EGFR 
used to circumvent inappropriate signaling in cancer (Raponi et al., 2008). 
1.2.1.1 The G protein Ras 
 Ras is a small GTPase which functions like a molecular switch to initiate the 
Ras/MAPK signaling cascade through its cycling between two conformational states: the GTP-
bound active state and the GDP-bound inactive state (Figure 1.2). Crystal structures of Ras 
proteins reveal a typical GTPase fold of 6 beta sheets surrounded by 5 alpha helices. Two loops 
near the nucleotide binding site are called “switch regions” because they undergo 
conformational changes when Ras switches activation states (Figure 1.2) (Shima et al., 2010; 
Milburn et al., 1990). The switch regions are important in effector recognition of Ras (Pacold et 
al., 2000; Nassar et al., 1995). When Ras is bound to GTP, main chain amine groups of both a 
threonine (Thr-35) from switch I (AA 30-38) and a glutamine (Gln-60) from switch II (AA 60-
75) make hydrogen bonds with the γ-phosphate group of GTP, while a conserved serine (Ser-
17) hydroxyl group displays charge-charge interaction with an essential Mg
2+
 ion (Shima et al., 
2010). The γ-phosphate interactions hold the switch loops in an ordered shape. In the GDP-
bound state, the missing hydrogen bonds with the γ-phosphate oxygens destabilize both flexible 
switch regions often resulting in disorder within the two loops (Vetter and Wittinghofer, 2001). 
Figure 1.2 Ras structure and activation. When bound to GDP (left) Ras cannot interact with its 
effector proteins and is in its inactive conformation. Guanine nucleotide exchange factors or GEFs 
facilitate the exchange of GDP for GTP, bringing Ras into its active conformation (right). Amino 
acids Thr35 and Gln60 make hydrogen bonds with the γ-phosphate of GTP, stabilizing the position 
of both switch I (purple) and switch II (red) loops. The Ser17 hydroxyl interacts with the charged 
Mg2+ ion. Effector proteins recognize the active conformation and are able to bind to Ras. GTPase 
activating proteins or GAPs enhance the GTPase activity of Ras, converting GTP to GDP and 
completing the Ras activation cycle. Crystal structures from PDB, ID SP21 (left), 4Q21 (right). 
Dashed black lines indicate hydrogen bonding. 
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Interaction with Ras and other small GTPases depends on the conformation of the switch 
regions, and thus by alternating between GDP- and GTP-bound states they become the on/off 
switch of downstream events. 
 Regulation of small GTPases, or G proteins, involves both guanine nucleotide exchange 
factors (GEFs) and GTPase activating proteins (GAPs) to efficiently bind and hydrolyze GTP, 
respectively. Ras requires a GEF to exchange its bound GDP for GTP in order to be activated. 
The GEF facilitates the release of GDP by destabilization of the nucleotide binding site in a 
push-and-pull mechanism whereby the switch I region is pushed out of position and the switch 
II region is pulled toward the nucleotide binding site (Vetter and Wittinghofer, 2001). Upon 
GTP binding, Ras interacts with its effectors, such as Raf, via switch regions epitopes, which 
are only presented in the active conformation. Deactivation of Ras requires the hydrolysis of 
GTP, which can be achieved through its intrinsic GTPase ability, though the rate of reaction is 
slow. Stimulation of GTP hydrolysis by GAPs, which provide a catalytic “arginine finger” 
residue as well as stabilization of the switch regions, ensures proper temporal regulation of Ras 
(Fidyk and Cerione, 2002). 
1.2.1.2 Signaling cascade downstream of Ras 
 Activation of Ras is tied to RTK signaling by its GEF Son of Sevenless (SOS). The 
Ras/MAPK (ERK) pathway becomes active after RTK phosphorylation, which recruits the SH2 
domain of adaptor protein Grb2 either directly (Figure 1.1) or indirectly through interaction 
with Shc (which also binds to pY on RTKs) (Reeby et al., 2012). Once Grb2 is recruited to the 
plasma membrane, the Grb2 Src homology 3 (SH3) domain interactions with the proline rich 
region on SOS, thus bringing the GEF proximal to its substrate Ras-GDP (Egan et al., 1993). 
SOS facilitates the exchange of Ras-bound GDP for the more abundant GTP. Activated Ras-
GTP recruits Raf, a serine/threonine kinase, from the cytoplasm to the plasma membrane where 
it is activated itself by phosphorylation (Roskoski, 2010). A cascade of protein activation by 
phosphorylation continues with Raf phosphorylation of MAPK/ERK kinase (MEK), to MEK 
phosphorylation of MAPK/ERK which then phosphorylates many proteins and transcription 
factor targets (Sebolt-Leopold and Herrera, 2004).  
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MAPK/ERK signaling affects cell cycle regulation through the inhibition of cyclin 
dependent kinase inhibitors p21
WAF1/CIP1
 and p27
KIP1
. Growth advantages in tumors with 
abnormal activation of the Ras/MAPK pathway are due to the downregulation of the pro-
apoptotic function of Bcl-2 associated with death (BAD) as well as transcription of pro-survival 
genes through the cAMP response element binding protein (CREB) transcription factor. 
Additional gene expression through the activation of transcription factors including c-Fos, 
signal transducer and activator of transcription (STAT)1 and STAT3 (Sebolt-Leopold and 
Herrera, 2004; Figure 1.1) by MAPK/ERK may also play a role in tumorigenesis. Some of the 
protein targets of this pathway are activated by phosphorylation, i.e. ribosomal S6 kinase 
(p90RSK) and MAPK-interacting kinase (MNK), while others are inactivated, i.e. tuberous 
sclerosis complex (TSC) (De Luca et al., 2012; Figure 1.1). The pathway is subject to negative 
feedback regulation, reducing the magnitude or duration of its activation. It has been shown in 
different cell lines that transient MAPK/ERK activation has different biological outcomes than 
those associated with sustained MAPK/ERK activation (Andreadi et al., 2012).   
1.2.2 Phosphatidylinositol 3′-kinase/Akt signaling 
 Other SH2-containing proteins act as adaptors, binding the pY residues of activated 
RTKs and effector proteins with separate domains, linking their activity to growth factor 
binding. PI3K is recruited by activated receptor pY residues and phosphorylates its lipid 
substrate phosphatidylinositol-4,5-bisphosphate (PtdIns-4,5-P2) at the 3′ OH of the inositol ring, 
creating PtdIns-3,4,5-P3 at the plasma membrane (Figure 1.1). PtdIns-3,4,5-P3 is an important 
second messenger in the PI3K/Akt pathway, as it recruits proteins with a pleckstrin homology 
(PH) domain, such as Akt, to membranes enriched in this phospholipid. Activation of Akt 
serine/threonine kinase activity by phosphorylation results in the phosphorylation of its target 
proteins (as many as 50 proteins have been characterized) which can induce an anti-apoptotic 
response, cell cycle progression and/or cell growth (Manning and Cantley, 2007; Vasudevan 
and Garraway, 2010). Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) 
acts to downregulate this pathway by dephosphorylating PtdIns-3,4,5-P3 at the 3′ position, 
inhibiting the recruitment of Akt and reducing the signal generated by the activated receptor.  
 
7 
 
1.2.2.1 Phosphatidylinositol 3′-kinase 
 PI3K is an obligate heterodimer consisting of a regulatory subunit and a catalytic 
subunit (Hirsch et al., 2007). PI3Ks are subdivided into three classes based on differences in 
structure and substrate specificity (Vanhaesebroeck and Waterfield 1999). The class I PI3K 
catalytic subunits are p110 proteins, and are expressed as different isoforms p110α, p110β, 
p110δ, and p110γ. All p110 proteins are responsible for the kinase activity of PI3K on their 
substrate PtdIns-4,5-P2. Regulatory subunits of class IA PI3Ks may be one of p85α, p55α, 
p50α, p85β, or p55γ. Only p110γ pairs with the regulatory subunit p101 and is therefore 
classified as Class IB.  
 Class IA PI3Ks (from now on designated only as “PI3K”) are the most studied because 
of frequent mutations found in both the gene of the p110α catalytic subunit PIK3CA and the 
p85α regulatory subunit gene PIK3R1 (Vogt et al., 2010; Yuan and Cantley, 2008). Oncogenic 
mutation of either gene can result in the increased activation of the catalytic subunit of PI3K, 
p110α, which leads to increased activation of Akt and downstream signaling (Samuels and 
Waldman, 2010; Cheung et al., 2011; Sun et al., 2010). The loss of PTEN, a tumor suppressor 
gene, (by loss of function mutation or loss of heterozygosity) also leads to increased Akt 
signaling by lack of dephosphorylation of PtdIns-3,4,5-P3 (Nardella et al., 2011). Because of its 
importance in signal transduction and its frequent mutation in cancer, PI3K has been studied 
extensively.  
1.2.2.1.1 Regulatory subunit: p85 
 The regulatory subunit of PI3K is encoded by three genes: PIK3R1 (p85α; can also be 
expressed as splice variants p50α and p55α), PIK3R2 (p85β), and PIK3R3 (p55γ). The smaller 
isoforms p50α, p55α and p55γ are composed an inter-SH2 (iSH2) domain which is flanked by 
two SH2 domains (Figure 1.3). Interaction between the iSH2 domain and the catalytic subunit, 
p110, confers stability to both proteins by protecting p110 from degradation (Klippel et al., 
1993). The iSH2 domain is a hotspot for mutation in cancers, specifically glioblastomas and 
endometrial cancers (Sun et al., 2010; Jaiswal et al., 2009; Cheung et al., 2011). Mutations in 
this region are tumorigenic when they disrupt p110 inhibition (discussed in section 1.2.2.1.3) 
without affecting the stabilizing contacts between the proteins (Gabelli et al., 2010). The larger 
isoforms p85α and p85β contain an N-terminal SH3 domain, two proline rich domains, and a  
 p50/p55 
 p85 
p110α/β 
p110β-specific 
p110α-specific 
Stabilization contacts 
both isoforms 
Inhibitory contacts: 
Legend: 
SH3 BH nSH2 iSH2 cSH2 
ABD RBD C2 Helical Kinase 
NH2 
NH2 
NH2 
COO- 
COO- 
COO- 
R274 
P
R
O
 
P
R
O
 
Figure 1.3 Domain structure of PI3K subunits. A. Domains of the regulatory subunit of 
phosphatidylinositol-3`-kinase smaller isoforms, p50 and p55, and B. larger isoforms, p85. SH3, 
Src homology 3 (interacts with proline rich domains); SH2, Src homology 2 (interacts with 
phosphorylated tyrosine motifs); PRO, proline rich domain; BH, Breakpoint cluster region 
homology (GAP domain); R274, arginine finger; iSH2, inter-SH2 domain (interacts with p110). C. 
Domain structure of catalytic subunit p110. ABD, adaptor binding domain (main interaction with 
p85); RBD, ras binding domain; C2, calcium binding-homology domain. The iSH2 interaction with 
ABD enhances the stability of p110. Regulatory contacts are indicated with red and purple arrows.  
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Breakpoint Cluster Region homology domain (BH) in addition to the two SH2 domains and 
iSH2 found in the smaller isoforms (see Figure 1.3). Both large isoforms of the regulatory 
subunit, p85α and p85β, are expressed ubiquitously in cells, though p85β to a lesser degree 
(Hirsch et al., 2007; Ueki et al., 2003). The large isoforms will be the focus of this thesis, 
specifically p85α.  
1.2.2.1.2 Catalytic subunit: p110 
 As mentioned, the catalytic subunit of PI3K has three isoforms which are encoded on 
separate genes. PIK3CA encodes p110α, PIK3CB encodes p110β, and PIK3CD encodes p110δ. 
Both p110α and p110β are ubiquitously expressed; whereas p110δ is expressed in immune cells 
only and therefore will not be characterized in this thesis (See review Patton et al., 2007 for 
more about p110δ). The p110 proteins have five domains: the N-terminal adaptor binding 
domain (ABD) which interacts with the iSH2 of regulatory subunits, the Ras binding domain 
(RBD), the C2 domain, the helical domain and the kinase domain (Figure 1.3). Structurally, 
p110α and p110β are very similar, though they diverge from each other in the RBD (Zhang et 
al., 2011).  
 The p110α and p110β isoforms can be activated downstream of different signaling 
pathways. Signals and effects downstream of the PDGFR were found to be impaired by p110α 
inhibition with neutralizing antibodies, but not by p110β inhibition (Ilic and Roberts, 2010). 
Conversely, downstream signaling from G-protein coupled receptors (GPCRs) is effected by 
p110β knockdown only (Jia et al., 2008; Ciraolo et al., 2008). It has been shown, however, that 
both isoforms have some involvement in insulin signaling (Chaussade et al., 2007; Jia et al., 
2008; Ciraolo et al., 2008; Foukas et al., 2006). Therefore, the two isoforms are considered to 
have partial functional overlap.  
1.2.2.1.3 Regulation of PI3K 
 In resting cells, p85 is bound to p110 and provides inhibition of the kinase by: 1) 
contacts between the p85 nSH2 domain to the p110 helical and kinase domains, 2) additional 
contacts between the p85 iSH2 and the p110 C2 domain, and 3) sequestration of p110 in the 
cytosol, away from its membrane-delimited lipid substrates (Figure 1.3). During growth factor 
receptor signaling, i.e. EGF or insulin-like growth factor-1 (IGF-1) stimulation, the SH2 
domains of p85 are recruited to phosphorylated tyrosine residues on EGFR or IGF receptor (Hu 
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et al., 1992; Yamamoto et al., 1992; Mellor et al., 2012). This brings the catalytic domain in 
proximity to its lipid substrate PtdIns-4,5-P2 at the plasma membrane. The nSH2 domain has a 
greater affinity for pY residues than it does for the helical and kinase domains of p110. Thus, 
p85 binding to pY residues releases the SH2 domain-mediated inhibition of p85 on p110, 
activating the kinase (Yu et al., 1998). The phosphatase agonist of PI3K, PTEN, 
dephosphorylates the lipid second messenger, regulating the time and intensity of the signaling 
event (De Luca et al., 2012).  
 The recent solution of the crystal structure of p85 domains with different p110 isoforms 
elucidated a difference in regulation between catalytic isoforms (Zhang et al., 2011). Both 
p110α and p110β are regulated by inhibitory contacts made between the iSH2 (p85) and C2 
(p110) domain as well as the nSH2 (p85) domain with both the helical and kinase (p110) 
domains. Regulation of p110β is also dependent on additional contacts with the cSH2 domain 
of p85. Though the p110β isoform is regulated by a “three brake” mechanism of p85 inhibition, 
i.e. the nSH2, iSH2 and cSH2 contributions, it is not more tightly controlled than p110α 
because amino acid differences in the p110β C2 domain render the p85 iSH2 inhibition 
ineffective (Vogt, 2011). Therefore both isoforms are regulated by two inhibitory contacts with 
the regulatory subunit p85.  
1.2.2.1.4 PI3K in cancer 
 In some cancers, the catalytic activity of p110α is enhanced by mutations E542K, 
E545K and/or H1047R in the hotspot helical and kinase domains through disruption of p85 
inhibitory contacts, releasing p110 from growth factor-dependent regulation by the nSH2 
domain (Samuels et al., 2004). In fact, point mutations in the helical and kinase domains 
accounts for 80% of all oncogenic PIK3CA mutations (Samuels and Waldman, 2010). 
Constitutive activation of p110α can lead to increased downstream signaling in the absence of 
growth factor, thus conferring a growth advantage. An engineered protein chimera containing 
full-length p110α and the iSH2 domain of p85 attached N-terminally by a glycine linker was 
found to be constitutively active (Klippel et al., 1995). Without the inhibitory contacts between 
the nSH2 domain and the helical and kinase domains, this p110 was both stabilized and 
disinhibited.  
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 In contrast, overexpression of wild-type p110β was sufficient to induce tumorigenesis, 
but mutations of the C2 domain of this isoform, e.g. mutations that would effectively activate 
p110α, were not (Kang et al., 2005; Dbouk et al, 2010). Additionally, p110β kinase activity, 
and not the activity of p110α, was necessary for the progression of prostate tumors lacking the 
tumor suppressor PTEN (Jia et al., 2008). Thus it suggested that p110β is less regulated than 
p110α, and promotes basal levels of PtdIns-3,4,5-P3 and downstream signaling in the absence of 
growth factor.  
1.2.2.2 Akt signalling 
The serine/threonine Akt is a master regulator of multiple cellular responses including 
cell survival, cell growth, cell proliferation, and glucose homeostatis due to its substantial 
repertoire of substrates (Vasudevan and Garroway, 2010; Figure 1.1). Activation of Akt 
requires both recruitment to the plasma membrane, as mentioned above, and phosphorylation of 
Thr-308 by phosphoinositide dependent kinase (PDK-1) and Ser-473 by mammalian target of 
rapamycin complex 2 (mTORC2) (Stokoe et al., 1997; Sarbassov et al., 2005) in response to 
growth factor binding to RTKs. To promote cell survival, active Akt phosphorylates the pro-
apoptotic protein BAD, which then becomes bound and sequestered by 14-3-3 proteins, 
inhibiting its apoptotic function (Datta et al., 1997; Datta et al., 2000). A second example of 
Akt-mediated cell survival is the phosphorylation of MDM2, which increases the stability of 
MDM2 in the nucleus and its E3 ubiquitin ligase activity, leading to the downregulation of p53-
mediated apoptosis (Zhou et al., 2001).  
Akt affects cell proliferation by promoting the G1-to-S phase cell cycle transition by 
phosphorylating and inactivating glycogen synthase kinase-3β (GSK-3β), which then can no 
longer act to downregulate cyclins D1 and E (Diehl et al., 1998; Welcker et al., 2003). The 
effect of PI3K/Akt signaling on cell growth manifests mainly through mTORC1 which is 
involved in the increase of protein synthesis (Vivanco and Sawyers, 2002). mTORC1 activation 
by Akt is indirect. Akt inactivates tuberous sclerosis complex 2 (TSC2) by phosphorylation. 
TSC2 is a GAP – or GTPase activating protein – to the Ras family member Rheb. Inactivation 
of TSC2 leads to an increase in active Rheb, which then interacts with and activates mTORC1 
(Manning and Cantley, 2007). Many more Akt phosphorylation targets exist in the cell, 
including kinases, adaptor proteins, and transcription factors such as FOXO1, which can be 
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found in more extensive Akt reviews such as Manning and Cantley (2007) as well as 
Vasudevan and Garroway (2010). Down regulation of PI3K/Akt signaling is achieved by 
dephosphorylation of both PtdIns-3,4,5-P3 by PTEN in order to stop further activation of Akt, 
and dephosphorylation of active Akt itself at Thr-308 by protein phosphatase 2A (PP2A), and at 
Ser-473 by PH-containing leucine-rich repeat protein phosphatase (PHLPP)1 and PHLPP2 
(Brognard et al., 2007). 
1.3 Endocytosis of activated RTKs 
Receptors undergo endocytosis when they are internalized into independent vesicles at 
the plasma membrane. Known mechanisms of internalization include clathrin-mediated (which 
will be discussed first) and caveolin-mediated (or clathrin-independent) endocytosis. The first 
step of clathrin-mediated internalization is the formation of protein complexes, or “nucleation”, 
at the plasma membrane which causes the formation of pits containing specific cargo, such as 
activated receptors. Some adaptor proteins, such as epsin 1 & 2, epidermal growth factor 
receptor pathway substrate 15 (EPS15) and FER/CIP4 homology domain only (FCHO) 
proteins, promote the membrane curvature necessary to form pits by insertion of their wedge 
shape into the membrane (McMahon and Boucrot, 2011). The multi-subunit adaptor protein, 
AP-2, coats the cytoplasmic face of the pits and provides an interaction point between plasma 
membrane lipids, receptor cargo and clathrin. Clathrin “triskelia” subunits assemble to support 
the curvature of the pits by coating their cytoplasmic surface (McMahon and Boucrot, 2011). 
The vesicle membrane is pinched off from the plasma membrane by the large GTPase dynamin 
(Praefcke and McMahon, 2004). It has been recently suggested that asymmetrical membrane 
protrusions can form a cap over clathrin-coated pits in an alternative method of closure 
(Shevchuk et al., 2012).  
Clathrin-independent endocytosis is less well understood. Plasma membrane domains 
that contain high concentrations of cholesterol and sphingolipids can deform into pits and have 
been called caveolae or “little caves” (Andersson, 2012). Caveolae are coated with the hairpin-
shaped protein caveolin-1 that interacts with cholesterol (Doherty and McMahon, 2009). These 
pits have been implicated in a pathway of internalization distinct from the clathrin-dependent 
pathway. Endocytosis by caveolae is less frequent than clathrin-mediated endocytosis, and 
some believe that these structures play an important role in stabilizing protein complexes on the 
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plasma membrane rather than in their internalization (Hansen and Nichols, 2009; Howes et al., 
2010). Flotillin proteins are similar in structure to caveolin and may provide a parallel 
internalization pathway (Andersson, 2012). Dynamin plays an important role in many 
internalization pathways including clathrin-, caveolae-, and flotillin-mediated endocytosis, but 
there are some pathways that act independently of dynamin and employ actin instead for 
membrane scission (Doherty and McMahon, 2009).  
Activated RTKs have been generally found in clathrin-coated vesicles after 
internalization and these seem to be important for downstream signaling (Sorkin and von 
Zastrow, 2009). A study of transforming growth factor β receptor (TGFβR) endocytosis 
suggested that the method of receptor internalization affected the outcome of signaling. It has 
been demonstrated that EGFR is internalized exclusively by clathrin-dependent endocytosis in 
low ligand concentrations (Sigismund et al., 2008). At high concentrations of EGF, EGFR is 
internalized via both clathrin and non-clathrin endocytosis (Sigismund et al., 2005). The latter 
is dependent on cholesterol and ubiquitination of the receptor, and results in receptor 
degradation (Sigismund et al., 2005). When TGFβR is internalized by clathrin, it leads to 
downstream signalling, whereas internalization by caveolae leads to receptor ubiquitination and 
degradation in the lysosome (Di Guglielmo et al., 2003).  
The removal of the receptors from the plasma membrane by endocytosis affects their 
overall signal output by reducing the concentration of receptors available to bind ligand. Also 
the physical relocation of activated receptors to vesicles within the cytoplasm or “endosomes” 
results in a bias towards soluble effectors over plasma membrane-associated effectors. 
Therefore, plasma membrane delimited proteins may only interact with growth factor receptors 
until they are internalized (Sorkin and von Zastrow, 2009). In this way, endocytosis provides 
temporal regulation of growth factor signal transduction by limiting the time of interaction 
between activated receptors and certain effectors. However, it has been shown that signaling 
from endosomes occurs as well (Vieira et al., 1996). Many effector proteins complex with β-
arrestins and/or scaffolding proteins containing a Fab1 YOTB Vac1 EEA1 (FYVE) zinc-finger 
domain or a PX domain which are specific for the phosphoinositide lipids present on endosomal 
membranes (Sorkin and von Zastrow, 2009). The early endosome, in which internalized 
receptors are found, has also been named the “signaling endosome” for this reason. Detection of 
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components of both PI3K/Akt and Ras/MAPK signaling cascades on endosomes suggests that 
these pathways remain activated after receptor internalization. 
1.4 RTK intracellular trafficking 
After internalization, the vesicle containing activated receptors (which may now be 
called an “early endosome”) is uncoated of clathrin or caveolin-1 and adaptor proteins 
(Stenmark, 2009). Internalized receptors in the early endosome dissociate from their ligand due 
to the lower pH of the organelle (Cain et al., 1989). The method of internalization and the post-
translational modifications of the receptor – including ubiquitination and phosphorylation –
determine the fate of the receptor. Possible fates include sorting for recycling back to the 
plasma membrane or sorting for degradation of the receptor in the lysosome. Receptors can be 
monoubiquitinated after internalization via clathrin-independent endocytosis which leads to 
sorting for degradation. Without this monoubiquitination signal, the receptor is recycled 
(Acconcia et al., 2009). Polyubiquitination of the receptor before clathrin-dependent 
internalization increases the affinity of adaptor proteins with ubiquitin binding domains such as 
epsin, leading to more efficient nucleation. The choice of internalization pathway can be 
regulated by the concentration of ligand, as mentioned in the case of EGF (Sigismund et al., 
2008), or through disruption of clathrin-mediated endocytosis by potassium depletion, which 
prevents clathrin lattice assembly (Vercauteren et al., 2010; Larkin et al.,  1986) or by 
expression of a dominant negative Eps15 (Di Guglielmo et al., 2003).  
Receptor trafficking is tailored to specific receptor needs. Some receptors are 
constitutively internalized (ligand-independent) and recycled to maintain cell sensitivity; i.e. the 
transferrin receptor which is important to maintain cellular iron homeostasis (Wang and 
Pantopoulos, 2011), the dopamine receptor 2 in neurons (Li et al., 2012), and small amounts (1 
– 2%) of epidermal growth factor receptors Her2, Her3 and Her4 (Wiley and Burke, 2001). The 
trafficking of other receptors is ligand-dependent and may at times be recycled or degraded in 
order to control their signal output, i.e. EGFR (Sigismund et al., 2008) and TGFβR (Di 
Guglielmo et al., 2003). There is also evidence of basal, ligand-independent receptor 
degradation through the actions of the small isoforms of ankyrin, Ank105 and Ank120 
(Ignatiuk et al., 2006) which may be important in maintenance of steady state levels of 
receptors, such as PDGFR, on the plasma membrane. Another type of trafficking is the ligand-
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dependent recycling of receptors, i.e. dopamine receptor 2, through perinuclear recycling 
endosome for functional resensitization of the receptor (Li et al., 2012). The early trafficking 
steps of receptors through the early endosome are common regardless of the pathway, whereas 
later steps require the sorting into different Rab-protein containing endosomes (Leonard et al., 
2008).  
1.4.1 Rab proteins 
 Rab proteins (so named due to their homology to Ras: Ras-related in brain) are involved 
in the intracellular trafficking of vesicles. The evolution of distinct organelles within a cell 
suggests the necessity for trafficking cargo between these organelles and the plasma membrane. 
Rab proteins have been demonstrated to be involved in every step of vesicle trafficking from 
internalization, to vesicle coating (with clathrin and AP-2) and uncoating, to vesicle motility 
and to the fusion of the incoming membrane with its target organelle (Stenmark, 2009; 
McMahon and Boucrot, 2011). In growth factor receptor signaling attenuation, the trafficking 
of activated receptors through the early endosome to either the lysosome where they are 
degraded, or back to the plasma membrane requires multiple Rab proteins (Stenmark, 2009). 
Different Rab proteins are associated with specific vesicle trafficking pathways including: 
endocytosis to early endosomes (Rab5, Figure 1.4 A and B), early endosome recycling to the 
plasma membrane (Rab4, Figure 1.4 C), recycling endosome to plasma membrane (Rab11, 
Figure 1.4 D), late endosome to lysosome (Rab7, Figure 1.4 F), and late endosome to the trans-
Golgi network (Rab9, not pictured) (Seachrist and Ferguson, 2003; Zerial and McBride, 2001). 
The human genome encodes 60 Rab proteins which are part of the Ras superfamily of small 
GTPases. 
 Ras proteins, as described in section 1.2.1.1, incorporate into the plasma membrane via 
a post-translational cysteine farnesylation of the C-terminal C-A-A-X motif (A is an aliphatic 
amino acid, X is any amino acid except for leucine; Ahearn et al., 2011). While Rab proteins 
have structural similarity to Ras, they do not contain the farnesylation motif, but instead a dual 
geranylgeranyl motif, C-X-C or X-X-C-C at their C-terminus, which is recognized by Rab 
escort protein (REP) which is in turn recognized by Rab geranylgeranyl transferase (Rab 
GGTase or GGT-II) (Pfeffer and Aivazian, 2004; Leung et al., 2006). The doubly geranyl-  
Figure 1.4 Endocytic trafficking by Rab proteins. A. Receptors are internalized at the plasma 
membrane via a clathrin-dependent (CCV, clathrin-coated vesicle) or clathrin-independent 
mechanism. The resulting internalized vesicles are coated with Rab5 which recruits effector 
proteins to alter the lipid composition of the membrane. B. Internalized vesicles fuse together to 
form early endosomes through actions of EEA-1 and SNARE proteins (not shown). Within the 
early endosome, the receptors dissociate from their ligand and are sorted for further trafficking into 
Rab microdomains. C. Receptors sorted for fast recycling (2-5 mins after internalization) bud off 
the endosome in Rab4-positive vesicles and are returned to the plasma membrane. D. Slower 
recycling of receptors (12-30 mins) occurs in the recycling endosome which depends on Rab4 and 
Rab11. E. Early endosomes mature into late endosomes through the actions of Mon1 and the 
recruitment of Rab7 activating proteins. Receptors destined for degradation are internalized in 
multi-vesicular bodies (MVB) within the lumen of the late endosome. F. Late endosomes fuse with 
lysosomes and receptors are degraded. EGF, epidermal growth factor; EGFR, receptor; Tf, 
transferrin; TfR, receptor; DRD2, dopamine receptor 2; DA, dopamine.  
Nucleus 
Maturation 
Budding 
Budding 
Fusion 
Fusion A 
B 
C 
D 
E 
F 
Plasma Membrane 
CCV 
Rab7 
Lysosome 
Rab5 
Internalized 
vesicle 
Fast 
Recycling 
Endosome 
Rab4 
Rab5 
Early/Sorting 
Endosome 
Late Endosome 
Rab5 
Internalized 
vesicle 
Rab11 
Recycling 
Endosome 
clathrin-
independent  
MVB 
EGFR 
TfR 
DRD2 
EGF 
Tf 
DA 
Legend: 
Fusion 
16 
17 
 
geranylated Rabs are chaperoned by either REP or by a GDP dissociation inhibitor (GDI) which 
bind to and mask the hydrophobic geranylgeranyl moieties allowing the complex to exist in the 
cytosol (Leung et al., 2006; Figure 1.5).  
 During receptor endocytosis, the Rab-GDP:GDI complex is recruited to its target 
membrane by a GDI displacement factor (GDF) (Pfeffer and Aivazian, 2004). Displacement of 
the GDI by GDF frees the isoprenyl group which may then be incorporated into the target 
membrane. So, unlike membrane delimited Ras, GDP-bound Rab proteins move on and off 
membranes through the concerted actions of GDI and GDF. Once the Rab geranylgeranyl group 
is incorporated into the membrane, the Rab activation cycle resembles that of Ras. Rab protein 
nucleotide exchange is facilitated by a GEF and GTP hydrolysis is enhanced by a GAP. A study 
of fluorescent lipidated Rab proteins demonstrated that GDI affinity for Rab-GTP was several 
orders of magnitude lower than for Rab-GDP (Wu et al., 2010) making the deactivation of the 
Rab protein a prerequisite for displacement from the membrane by GDI.  
 Rab GTPases act by recruiting effector proteins to a specific endosome at the proper 
time. An additional level of organization is achieved by Rab “microdomains” on an endosome, 
where different Rab proteins co-exist within the same organelle, but remain enriched in discrete 
domains of the membrane (Zerial and McBride, 2001) (Figure 1.4, early endosome). The 
coordination of all trafficking events within a cell requires a complement of functional Rab 
proteins. Rab effector protein binding sites are only presented in the proper orientation in the 
GTP-bound Rabs and are unique in sequence or orientation from one Rab protein to another 
(Mishra et al., 2010). Protein complexes on vesicles and endosomes are therefore organized by 
the specific Rab available on the surface and only recruited when that Rab is in its active form. 
1.4.1.1. Rab5  
 Rab5 has three subgroup isoforms (A, B and C) with 81-90% sequence identity (Wilson 
and Wilson, 1992) which are encoded by separate genes. RAB5A is located on chromosome 17, 
RAB5B is on chromosome 2 and RAB5C is on chromosome 11 (Barbosa et al., 1995). The 
abundance of each Rab5 isoform is cell-type dependent (Chiariello et al., 1999; Chen et al., 
2009). All Rab5 isoforms co-localize with internalized transferrin and are involved in endocytic 
trafficking (Bucci et al., 1995). Differential phosphorylation of Rab5 isofroms has been  
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Figure 1.5 Rab protein geranylgeranylation and membrane recruitment cycle. A. Alignment 
of crystal structures of the Rab7: Rab escort protein 1 (REP1, PDB ID: 1VG0; blue) complex with 
Rab geranylgeranyl transferase (Rab GGTase, 1LTX; green). REP1 recognizes the C-terminal C-
X-C or X-X-C-C motif of the Rab, binds to it and recruits Rab GGTase which transfers two 
geranylgeranyl groups (right) to the Rab.  B.  The isoprenylated Rab exists in complex with either 
REP1 or guanine dissociation inhibitor (GDI, 2BCG; purple) in the cytoplasm in absence of 
receptor signaling and endocytosis. The hydrophobic C-terminal geranygeranylation (indicated with 
red arrows) is masked by REP1 or GDI. During receptor endocytosis, a GDI displacement factor 
(GDF) removes the bound GDI and facilitates Rab protein recruitment to the target membrane, 
where it can be activated. At the end of their activation cycle, GDP-bound Rab proteins can be 
removed from the membrane by GDI.  
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reported where Rab5B is phosphorylated by cdc2 kinase, Rab5A by ERK (Chiariello et al., 
1999). Rab5A siRNA knockdown and Rab5A overexpression have a greater influence on 
EGFR trafficking in HeLa and DU145 cells compared to the other Rab5 isoforms (Chen et al., 
2009). Because of its importance in RTK trafficking, Rab5A (which will hence be designated 
only as “Rab5”) is the focus of this thesis.  
 Rab5 is a typical Rab protein that cycles between nucleotide-bound states and 
membrane-bound to cytoplasmic locations, providing both spatial and temporal regulation of 
early endosomal trafficking. Interaction with a GDF brings inactive Rab5 from the cytoplasm to 
the plasma membrane, in response to growth factor stimulation, where it may be activated. The 
Rab5-GEF Ras and Rab interactor 1 (Rin1) is activated downstream of EGFR (Barbieri et al., 
2003) through binding of the Rin1 SH2 domain to phosphorylated tyrosine residues of the 
receptor. Other Rab5 GEFs exist, including Rabex-5 (Horiuchi et al., 1997), alsin (Topp et al., 
2004) and GAPex-5 (also called RME-6, RAP-6 and GAPVD1 because it has dual GEF and 
GAP activity) (Su et al., 2007). Though the GEFs have the overlapping function of activating 
Rab5, they may be specific to one isoform of Rab5 or act in different circumstances. After 
upstream receptor signaling, Rin1 is thought to be the first activator of Rab5, linking 
endocytosis to the activation of receptors (Jozic et al., 2012). On early endosomes, the binding 
of the Rab5 effector Rabaptin-5 induces a positive feedback loop of Rab5 activation by the 
recruitment of Rabex-5 (a binding partner of Rabaptin-5) and allows for the enrichment of 
active Rab5 on early endosomes, counteracting the intrinsic GTPase activity of Rab5 (Horiuchi 
et al., 1997; see Figure 1.6). Regulatory proteins of Rab5 are summarized in Table 1.1. 
 The role of active Rab5 is to recruit effector proteins that bind specifically to Rab5-
GTP. Active Rab5 is found at the plasma membrane as well as on early endosomal membranes 
(Ali et al., 2004). Rab5 has been associated with cargo selection into clathrin-coated membrane 
invaginations as well as clathrin-independent receptor internalization by macropinocytosis (or 
fluid-phase endocytosis; “cell drinking”) through its effector Rabankyrin-5 (Schnatwinkel et al., 
2004). Another important Rab5-mediated process is the modification of phosphatidylinositols 
on the early endosomal membrane by the concerted activity of Rab5 effectors. PI3K (section 
1.2.2.1), phosphatidylinositol 4`-phosphatase and phosphatidylinositol 5`-phosphatase enrich 
the early endosome with PtdIns-3-P (Shin et al., 2005) by generating and dephosphorylating the  
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Figure 1.6 Rab5 activation by different GEFs. A. Membrane recruitment of Rab5 by GDF 
displacement of GDI. B. Receptor-interacting GEF Rin1 activates Rab5 by exchanging bound GDP 
for GTP. Rab5-GTP recruits effector proteins such as Rabaptin-5 which bind to specific epitopes on 
active Rab5. C. Positive feedback loop whereby Rabex-5, which is recruited by active Rab5 
through its binding partner Rabaptin-5, enhances  Rab5 GDP for GTP exchange.  
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Protein Function  Reference 
Rin-1 GEF, downstream of receptor signalling Barbeiri, et al., 2003; 
Jozic et al., 2012 
Rabex-5 GEF, positive feedback on early endosomes Horiuchi et al., 1997 
Alsin GEF Topp et al., 2004 
GAPex-5 GEF/GAP Su et al., 2007 
Tuberin GAP Xiao et al., 1997 
RabGAP-5 GAP, arginine finger is R165 Haas et al., 2005 
PRC17 GAP, arginine finger is R107 Pei et al., 2002 
p85 GAP, arginine finger is R274 Chamberlain et al., 2004 
RN-tre GAP, arginine finger is R150,  
also acts on Rab41 
Lanzetti et al., 2000; 
Haas et al., 2005 
Table 1.1 Regulatory proteins of Rab5.  
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PtdIns-3,4,5-P3 lipid product, respectively (Figure 1.7). In addition, the class III PI3K, Vps34, 
directly generates PtdIns-3-P from PtdIns (Shin et al., 2005; Figure 1.7). Rab5 protein effectors 
with FYVE domains, i.e. EEA-1 and Rabenosyn-5, interact with both Rab5 and PtdIns-3-P on 
early endosomes to form a tether between two early endosomes. The proximity of the two 
vesicles allows membrane anchored proteins called soluble N-ethylmaleimide-sensitive 
attachment protein receptors (SNAREs) to interact in trans with high affinity, effectively 
mediating the fusion of vesicle membranes in what is called homotypic or lateral fusion 
(Woodman, 2000). 
 Expression of a dominant negative mutant of Rab5, i.e. Rab5-S34N which selectively 
binds GDP, results in the inhibition of both early endosomal homotypic fusion and receptor 
internalization by macropinocytosis (Barbieri et al., 2000). In its inactive conformation, Rab5 
cannot recruit the phosphatidylinositol modifying enzymes nor the FYVE-domain containing 
proteins required to bring early endosomes together. Thus, SNARE proteins cannot promote the 
homotypic fusion important for receptor cargo sorting in the early/ “sorting” endosome because 
their interaction requires the juxtaposition of the membranes to be fused (Woodman, 2000). 
Expression of Rab5-Q79L, which lacks GTPase activity such that it is locked in an active Rab5-
GTP conformation, in contrast, results in the formation of enlarged early endosomes (Barbieri 
et al., 2000) due to increased early endosome fusion.  
Several GTPase activating proteins of Rab5 have been discovered and include proteins 
tuberin (Xiao et al., 1997), RabGAP-5 (SGSM3) (Haas et al., 2005), PRC17 (TBC1D3) (Pei et 
al., 2002) and p85 (Chamberlain et al., 2004). All of these proteins have been shown to increase 
the rate of GTP hydrolysis compared to purified Rab5 alone. Additionally, the GAP activity of 
most of these proteins, except tuberin which was not tested, was abolished after mutation of a 
specific arginine residue, the catalytically important arginine finger (Table 1.1). The 
significance of having multiple GAPs for Rab5 is unknown, but may be a form of redundancy 
to ensure the appropriate inactivation of Rab5. The specificity of the aforementioned GAPs 
toward Rab5 isoforms has not been investigated.  
 The crystal structure of Rab5 has been determined, alone as well as in complex with 
some of its effectors (Zhu et al., 2003; Terzyan et al., 2004; Zhu et al., 2004; Eathiraj et al., 
2005; Mishra et al., 2010). The most studied effector of Rab5 is EEA-1, which is important for 
Figure 1.7 Generation of phosphorylated phosphatidylinositol signaling intermediates. 
Phosphatidylinositol (PtdIns) is a phospholipid component of the plasma membrane. Kinases and 
phosphatases act on the 3`, 4`and 5`hydroxyl groups to increase or decrease, respectively, protein 
affinity for the phospholipid. From the right, PtdIns-4,5-P2 is phosphorylated by 
phosphatidylinositol-3`-kinase catalytic subunit p110, making PtdIns-3,4,5-P3. This 
phosphorylation is antagonized by phosphatase PTEN. PtdIns-3,4,5-P3 recruits cytoplasmic proteins 
with a PH domain. Sequential dephosphorylation by PtdIns-4-Pase and PtdIns-5-Pase, either order, 
leads to the accumulation of PtdIns-3-P on endosomal membranes. Proteins with a FYVE finger 
domain interact with PtdIns-3-P and act to tether endosomal membranes together. Another method 
of PtdIns-3-P generation is through phosphorylation of PtdIns by Vps34, another 
phosphatildylinositol-3`-kinase. Lipid group (R) is as indicated in the figure (right). 
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docking or tethering the internalized vesicles with the early endosome. It is known that EEA-1 
interacts with both Rab5-GTP as well as PtdIns-3-P lipid, the latter through its FYVE-finger 
domain. A similar interaction is seen with Rab5 and Rabenosyn-5, which also has a FYVE 
domain. Because these proteins are effectors, they recognize an epitope on Rab5 which is 
unavailable in its GDP-bound inactive state.  
Crystal structures of Rab5 in complex with an effector require the protein to be in its 
active GTP-bound state. Since Rab5 has intrinsic GTPase activity, crystals are either prepared 
in the context of a GTPase-deficient mutant of Rab5 (e.g. Q79L) or, more commonly, with a 
non-hydrolysable GTP-analogue (Terzyan et al., 2004; Zhu et al., 2004). Examples of these 
GTP analogues include GTPγS (Guanosine 5′-[gamma-thio] triphosphate), which replaces a γ-
phosphate group oxygen with a sulfur atom, GppCp (Guanosine 5′-[β, γ methyleno]-
triphosphate) and GNP (Guanylyl 5′-[β, γ] imidodiphosphate) which replace the β-γ bridge 
oxygen with either carbon or nitrogen, respectively (Figure 1.8). By replacing GTP with one of 
these analogues, the hydrolysis reaction is impeded, in the case of GTPγS, or inhibited, keeping 
wild-type Rab5 in its active conformation. These minor changes in the structure of the 
nucleotide may affect some Rab5 contacts with its effectors, compared to what occurs in vivo, 
but this is the compromise for having a stable active-state Rab protein for binding studies. 
1.4.1.2 Rab4 and Rab11 recycling pathways 
 Rab4 and Rab11 are involved in the recycling pathway of RTK trafficking (Stenmark, 
2009). Both proteins can be found associated with the early endosomal membrane, though Rab4 
can be found within Rab4/Rab5 microdomains as well as Rab4/Rab11 microdomains (Zerial 
and McBride, 2001). Rab4 is essential for rapid recycling of cargo back to the plasma 
membrane, whereas Rab11 is involved in a slower recycling process that involves sorting 
through a recycling endosome before returning cargo to the plasma membrane (Stenmark, 
2009).  
 Recycling receptors back to the plasma membrane allows them to be activated again, 
and is important for sustained signaling especially when growth factor concentration is limiting. 
Rab4 is critical for the constitutive recycling important for maintaining steady-state levels of 
dopamine receptor 2 and transferrin receptors (Li et al., 2012). Rab11-positive recycling 
endosomes are found near the nucleus and are important for dopamine-stimulated recycling of  
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Figure 1.8 Non-hydrolysable GTP analogues. A. GTPγS (Guanosine 5′[gamma-thio]-
triphosphate. B. GppCp (Guanosine 5′[β, γ methyleno]-triphosphate, figure from 
www.jenabioscience.com. C. GNP (Guanosine 5′[β, γ]- imidotriphosphate). Modifications of the 
nucleotide are indicated with blue arrows. 
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the dopamine receptor 2, as shown in studies using dominant negative Rab11 mutants in 
cultured mouse striatal medium spiny neurons (Li et al., 2012). Through total internal reflection 
fluorescence microscopy (TIRFM) it has been discovered that Rab-11 is also implicated in the 
exocytosis of cargo in recycling endosomes, i.e. transferrin receptor, at the plasma membrane 
through fusion steps analogous to Rab5-dependent fusion of early endosomes (Takahashi et al., 
2012). The regulation of internalized receptor recycling seems to be determined by ligand 
binding and involves one of two routes: ligand-independent Rab4-mediated fast recycling or 
ligand-dependent Rab-11-mediated slow recycling through the recycling endosome.  
1.4.1.3 Rab protein domains and conversion of endosomes 
 Some Rab5 effector proteins also have affinity or a separate binding site for Rab4, 
which explains their combined microdomain on early endosomes. One such effector is 
Rabaptin-5 which binds both Rab5 and Rab4 via separate domains (Somsel-Rodman and 
Wandinger-Ness, 2000). In bringing Rab5 and Rab4 together in complex, Rabaptin-5 connects 
endocytosis with the recycling network. No such interactivity has been described between Rab5 
and Rab11.  
It is thought that some endosomal compartments undergo conversion or “maturation” as 
the lipid identity and associated coat-proteins are altered and replaced. The theory is compelling 
at least for early to late endosomal maturation, which has been used as a model for Rab-
mediated endosome conversion (Spang, 2009). The switch protein Mon1 is recruited to the 
early endosome and displaces Rabex-5, disrupting the Rab5 positive activation feedback loop. 
Mon1 also recruits the homotypic fusion and vacuole protein sorting (HOPS) complex, which is 
responsible for nucleotide exchange and activation of Rab7 (Poteryaev et al., 2010).  The Rab7-
GTP concentration increases due to the recruitment of HOPS and active Rab5 is reduced in time 
due to the activity of GAPs, therefore converting Rab identity of the early endosome (Rab5-
enriched) into a late endosome (Rab7-enriched). In the case of Rab4 or Rab11 recycling 
endosomes, it is believed that vesicle budding from early endosomes to a separate endosome 
occurs, rather than maturation.  
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1.5 GAP proteins 
GAPs provide two functions: a conserved arginine finger and stabilizing interactions 
with the switch regions of small monomeric GTPases (Fidyk and Cerione, 2002). GAPs may be 
multi-domain proteins that have a GAP, BH, or Tre-2/Bub-2/Cdc16 (TBC) domain. Conserved 
among these domains is the presence of a catalytic arginine finger. This arginine residue acts in 
three ways to enhance GTP hydrolysis. First, the backbone carbonyl forms a hydrogen bond 
with glutamine 61 of Ras (equivalent to Q79 of Rab5), which is known to draw the polar charge 
of the electrophilic water by hydrogen bonding (Figure 1.9). Second, the guanidinium 
functional group forms hydrogen bonds with oxygens of the α-phosphate, the α-β bridge, the γ-
phosphate and/or the β-γ bridge oxygen, stabilizing the transition-state (Figure 1.9). Third, the 
insertion of arginine into the nucleotide binding pocket displaces 5 water molecules, therefore 
decreasing the entropy of the reaction by as much as 40 kJ/mol (Kotting et al., 2007).  
Most studies of GAP activity have been explored in the context of Ras, and though 
much of what has been learned may be true for Rab protein regulation as well, not all will be 
transferrable. For example, many Rab GAPs contain a conserved TBC domain which functions 
through a two-finger mechanism: an arginine finger and a glutamine finger, though some 
unconventional TBC domain-containing proteins act through a single arginine finger (Pan et al., 
2006). There are 44 predicted TBC-containing proteins in the human genome; of these, 19 
TBCs whose substrates have been elucidated. Nineteen other RabGAPs have been identified 
(Frasa et al., 2012).  
Switch stabilization of small GTPases during GTP hydrolysis may also contribute to the 
effectiveness of a particular GAP. Because of the mobility of the switch region loops in the 
GDP conformation in most small GTPases, stabilization of these regions is a conserved 
function in the GAPs that regulate them. Mutation of arginine fingers to alanine in the GAPs 
p85 and p50rhoGAP reduced overall GAP function, but did not abolish it (Leonard et al., 1998; 
Chamberlain et al., 2004). In the co-crystal structure of Cdc42-p50rhoGAP contacts are made 
between the switch regions of Cdc42 and residues N414 and N422 of p50rhoGAP (Nassar et 
al., 1998). Mutation of these residues on p50rhoGAP greatly reduced its activity (Fidyk and 
Cerione, 2002) suggesting that contacts between switch regions of small GTPases and their 
GAPs are catalytically important.  
Figure 1.9 Arginine finger mechanism of action. A. Co-crystal structure of Ras (red) and 
p120rasGAP (green) with GDP·AlF4 (PDB ID: 1WQ1). The arginine finger of p120rasGAP, R789, 
enhances GTP hydrolysis by hydrogen bonding with Ras Q61 (indicated by arrow 1), which 
coordinates a water molecule, and by forming a hydrogen bond with the α-phosphate oxygen 
(arrow 2) and a covalent bond with γ-Al fluoride (arrow 3) to stabilize the transition state.  B. Co-
crystal structure of Rho (red) and p50rhoGAP (green) with GDP·AlF4 (PDB ID: 1TX4). The 
arginine finger of p50rhoGAP, R85, employs a similar hydrogen bonding pattern with Rho Q63 
(arrow 1), the α-phosphate (arrow 2) the α-β bridge (arrow 3) and the β-γ bridge (arrow 4) oxygens.   
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More than one GAP can regulate Rab5. Since Rab5 is an important component of the 
endocytic machinery it may have redundant regulators. Alternatively, the differential expression 
and subcellular distribution of GAPs, through other protein or lipid binding domains, may 
ensure that Rab5 inactivation occurs on distinct intracellular membranes in a timely manner 
(Frasa et al., 2012). Tuberin was the first described Rab5 GAP (Xiao et al., 1997). RN-tre was 
determined to have Rab5 GAP activity through its TBC domain (Lanzetti et al., 2000), though 
in HeLa cells it predominantly regulates Rab41 (Haas et al., 2005). PRC17, also known as 
TBC1D3, was identified as a gene amplified in prostate cancers and a protein overexpressed in 
both prostate and breast cancers. Its Rab5 GAP activity was determined to drive tumorigenicity 
in those cells (Pei et al., 2002). Other described Rab5 GAPs include RabGAP5, and p85. Some 
GAPs have activity towards more than one small GTPase target in vitro, i.e. TBC1D1 which 
regulates Rab2A, Rab8A, Rab8B, Rab10, and Rab14, though the in vivo relevance is unknown 
(Roach et al., 2007). Therefore, some of Rab5 GAPs mentioned may have additional Rab 
protein targets (including the different isoforms of Rab5) and could be important for Rab 
protein downregulation in a specific cellular context.  
1.5.1 Role for p85 in the regulation of Rab proteins 
 Though it is known as a regulatory subunit of PI3K, p85α has also been shown to have 
catalytic activity as a GAP towards Rab4, Rab5 (as mentioned previously), Rac1, Cdc42 and to 
a lesser extent Rab6 in vitro (Chamberlain et al., 2004) through its BH domain. The smaller 
isoforms of PI3K regulatory subunits do not contain the BH domain, and do not have GAP 
activity. The arginine finger of p85 has been identified as R274 (Chamberlain et al., 2004). 
Mutation of arginine 274 to alanine reduces GAP activity of purified p85 in vitro by 95% 
(Chamberlain et al., 2004). Though mutations in the BH domain are uncommon in cancers, 
p85-R274A was able to drive tumorigenesis in a xenograft mouse model (Chamberlain et al., 
2008) by increased and sustained MAPK activation (Chamberlain et al., 2004). The 
transforming phenotype of p85-R274A cells was reversed by the co-expression of dominant 
negative mutant Rab5-S34N, suggesting that the disruption of GAP activity towards Rab5 (and 
therefore increased Rab5-GTP) was the mechanism by which cells were transformed 
(Chamberlain et al., 2008). 
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 Interaction between Rab5 and PI3K has been investigated. Both the regulatory (p85) and 
catalytic (p110β) subunits have been found to bind to the small GTPase (Chamberlain et al., 
2004; Chirstoforidis et al., 1999; Kurosu and Katada, 2001). Specifically, GST pull-down 
assays have demonstrated GST-Rab5 binding to p85 regardless of its nucleotide-bound status, 
i.e. Rab5-GDP or Rab5-GTPγS (Chamberlain et al., 2004). Through yeast two-hybrid (Kurosu 
and Katada, 2001) and affinity columns (Christoforidis et al., 1999) the binding of Rab5 to the 
p110 β isoform has been shown. This interaction occurs only when Rab5 is in its active 
conformation (Christoforidis et al., 1999), which can be approximated by binding to non-
hydrolysable GTP analogues such as GTPγS. The binding site between p110β and Rab5-GTP 
has been narrowed down to residues 136-270 and 658-759 on the p110β protein (Kurosu and 
Katada, 2001). 
1.5.2 Non-catalytic involvement of p110 in trafficking 
The drug wortmannin is a pan-PI3K inhibitor which also affects early endosome 
morphology (Mills et al., 1999). At 100 nM, the inhibitor reduces PI3K activity by up to 80% 
(Martys et al., 1996) and its effect on downstream signaling can be evaluated by probing whole 
cell lysates with phospho-specific Akt antibodies. In many cell types, wortmannin treatment 
induces the formation of enlarged cytoplasmic vesicles (Chen and Wang, 2001a; Houle and 
Marceau, 2003) where endocytosed receptors are found. In wortmannin-treated cells, the 
degradation of receptors is sometimes increased, as in the case of bradykinin receptor and 
induced, in the case of the transferrin receptor (Houle and Marceau, 2003; Martys et al., 1996; 
Chen and Wang, 2001a). The enlarged vesicles are not affected by the replenishment of PI3K 
products, namely PtdIns-3-P, PtdIns-3,4-P2 and PtdIns-3,4,5-P3 in wortmannin-treated cells 
(Chen and Wang, 2001b), suggesting that although wortmannin inhibits PI3K lipid kinase 
activity, p110 also has a role in endocytic trafficking which is being disrupted by the drug. 
Similar enlarged early endosomes can be seen when the active conformation mutant Rab5-
Q79L is expressed in cells (Barbieri et al., 2000; Chen and Wang, 2001a) as mentioned in 
section 1.4.1.1. Also, the wortmannin-induced formation of enlarged vesicles is inhibited by 
expression of Rab5-S34N (Houle and Marceau, 2003; Hunyady et al., 2002; Chen and Wang, 
2001a, b). Therefore, a Rab5-mediated function of receptor trafficking requires a kinase-
independent function p110. 
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Genetic knock-out of either PIK3CA (p110α) or PIK3CB (p110β) results in early 
embryonic death in mice, but knock-ins of catalytically dead p110β lead to survival in mice, 
though their growth lagged behind wild-type p110β-expressing mice (Ciraolo et al., 2008). 
Additionally, endocytic trafficking of both transferrin and EGFR were altered when p110β was 
knocked out or expressed at lower levels (Ciraolo et al. 2008; Jia et al., 2008) but they were 
restored to normal by the re-expression of the kinase-dead mutant p110β. These data support 
the idea that p110β has some function within the endocytic pathway that is unrelated to its 
kinase activity.  
We postulate that p85 and p110β act together to provide the catalytic arginine finger and 
the switch stabilization features of a GAP, respectively, in order to inactivate Rab5 and shut 
down receptor trafficking. This cooperative heterodimer model of GAP activity is extremely 
rare and has not been described in the literature for Rab proteins. Some GAPs have been shown 
to act as homo- and hetero-dimers for other GTPases. For example, regulators of G-protein 
coupled receptor signaling (RGS) can form complexes with the subunits of the heterotrimeric 
G-protein coupled receptors (GPCRs) to promote GAP activity (Snow et al., 1998). Another 
example is CAPRI, a GAP with activity towards Ras and Rap1, which alters its substrate 
specificity by Ca
2+
-dependent homodimerization (Dia et al., 2011). Also, plant-specific Rho 
(ROP) GAPs have also been found to act as homodimers (Schaefer et al., 2011). However, in 
the regulation of Rab GTPases, GAPs are normally monomeric (Frasa et al., 2012; Paduch et 
al., 2001). 
In order to assess the validity of the p85/p110 heterodimeric GAP model, the binding 
sites between these two proteins and Rab5 should be determined. Residues which bind and 
stabilize the switch regions of Rab5 have not been identified in the structure of p85, and may be 
provided by its binding partner, p110β. The binding sites of p85 and p110β on the Rab5 protein 
were sought using site-directed mutation and pull-down experiments. Non-binding mutants 
generated in this thesis (i.e. p110β∆Rab5 and/or Rab5∆p110β) will be used in future research to 
test if there is p85/p110β cooperation in regulating the GTPase activity of Rab5. 
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2.0 HYPOTHESIS AND OBJECTIVES 
2.1 Rationale 
 The regulation of the nucleotide bound status of Rab5 requires both GEFs and GAPs 
(Paduch et al., 2001; Stenmark, 2009; McMahon and Boucrot, 2011). Our lab has identified the 
regulatory subunit of PI3K, p85, to be a GAP for Rab5 (Chamberlain et al., 2004). Mutation of 
its arginine finger greatly reduced GAP activity but did not abolish it (Chamberlain et al., 
2004). Other studies have shown that a second function of GAP proteins is to provide 
stabilizing contacts to the mobile switch regions of small GTPases (Fidyk and Cerione, 2002). 
No such interaction has been identified between p85 and Rab5, as p85 binds to both Rab5-GDP 
and Rab5-GTP (Chamberlain et al., 2004) despite their differences in switch region 
conformation. A binding partner of p85, p110β, binds to Rab5 in its GTP-bound state only 
(Christoforidis et al., 1999; Kurosu and Katada, 2001). Therefore, this thesis proposes that p85 
and p110β act together to perform the two functions of a GAP: p85 providing the catalytic 
arginine finger and p110β providing the switch region stabilization. The regulation of p85 and 
p110β towards Rab5 can be evaluated by disruption of contact regions between Rab5 and p85 
as well as Rab5 and p110β. In order to disrupt binding, the regions of contact between the 
proteins must first be identified.  
2.2 Hypotheses 
 The hypotheses of this work were two-fold: I) The binding of p85 to Rab5 is 
conformation-independent and involves Rab5 amino acids outside of the switch regions. II) The 
binding of p110β to Rab5 is conformation dependent and involves Rab5 amino acids within the 
switch I (AA 42-52) and/or switch II (AA 77-95) regions of Rab5.  
2.3 Objectives 
The objectives of this thesis were: 
 1) To determine the p85 binding site on Rab5 by pull-down experiments with wild-type 
 FLAG- p85 and immobilized Rab5 non-switch region mutants.  
2) To determine the p110β binding site by pull-down experiments with Myc-iSH2-p110β and 
 immobilized Rab5 switch region mutants.  
3) To determine the Rab5 binding site on p110β by pull-down experiments using immobilized 
 wild-type Rab5 and Myc-iSH2-p110β mutations in the Ras-binding domain. 
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3.0 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Mammalian cells 
COS-1 Cercopithecus aethiops (green monkey) SV40 transformed kidney cells from the 
American Type Culture Collection (#CRL-1650) were used in transient transfections to 
overexpress FLAG-p85 and Myc3-iSH2-p110α/β protein.  
3.1.2 Yeast strains 
Yeast two-hybrid experiments were performed using two strains of Saccharomyces 
cerevisiae: EY111 (MATα, his3, trp1, ura3::LexA8op-lacZ, ade2::URA3-LexA8op-ADE2 
leu2::LexA6op-LEU2) and EY93 (MATa, ura2, his3, trp1, leu2, ade2::URA3) (Barreto et al., 
2009) both generously provided by Dr. Ronald Geyer (University of Saskatchewan). 
3.1.3 Bacterial cells and culture 
DNA amplification was performed within the Escherichia coli (E. coli) strain TOP10 [F
-
, mcrA, D(mrr-hsdRMS-mcrBC), f80lacZDM15 DlacX74, deoR, recA, araD139 D(ara-
leu)7697, galK, rpsL(StrR), endA1, nupG] (Invitrogen). GST-fusion proteins were 
overexpressed in protease-deficient BL21 [E. coli B, F-, dcm, ompT, hsdS(rb-mb-), gal] cells 
(Amersham). Both bacterial strains were grown in Millar's Luria Bertani broth (LB, Sigma-
Aldrich), supplemented with 100 µg/mL ampicillin (Sigma-Aldrich), at 37°C in a shaking 
incubator. 
3.1.4 Antibodies 
All antibodies were purchased from Santa Cruz Biotechnology, with the exception of 
anti-FLAG-M2 (Sigma-Aldrich Canada, Ltd.; Oakville, ON) and anti-p85 nSH3 (Millipore; 
Billerica, MA). Secondary antibodies were goat anti-mouse or goat anti-rabbit conjugated to 
infrared dye (LI-COR Biosciences; Lincoln, NB) and were visualized using LI-COR imaging 
and Odyssey software V3.0. All antibodies used are summarized in Table 3.1.  
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Table 3.1 Primary and secondary antibodies used to probe protein blots.  
Antibody Name, species Company and Cat. # Figure(s) Concentration 
used 
Anti-FLAG (M2), mouse Sigma-Aldrich, F3165 4.1, 4.4, 4.5 10 µg/mL 
Anti-PI3K p85 N-SH2, mouse Millipore, 05-217 4.1, 4.8 1 µg/mL 
Anti-Rab5 (FL-215), rabbit 
Santa Cruz Biotechnology, 
SC-28570 
Not shown 10 µg/mL 
Anti-Myc-C (A14), rabbit 
Santa Cruz Biotechnology, 
SC-789 
4.9, 4.11, 4.13 10 µg/mL 
IRDye 680 Anti-Mouse, goat 
LI-COR Biosciences, 926-
32220 
4.1, 4.4, 4.5, 
4.8 
0.132 µg/mL 
IRDye 680 Anti-Rabbit, goat 
LI-COR Biosciences, 926-
32221 
4.9, 4.11, 4.13 0.132 µg/mL 
IgG AC (normal), mouse 
Santa Cruz Biotechnology, 
SC-2343AC 
4.8 10 µg/ 0.5 mL 
Myc mAb (agarose 
conjugated), mouse 
Santa Cruz Biotechnology, 
SC-14428AC 
4.8 10 µg/ 0.5 mL 
3.1.5 Plasmids and vectors 
Both p85α (human) and Rab5A (dog) cDNAs were subcloned separately into pGEX6P1 
vector (Amersham). All GST-Rab5 mutants were generated within this construct, which has 
two amino acid substitutions (S3N, N210S) compared to human Rab5. The human cDNA of 
Rab5A was subcloned into the vector pGEX3X, which is similar to pGEX6P1 except it 
contains a Factor Xa cleavage site instead of a PreScission protease cleavage site in the multiple 
cloning site (Amersham).  The p110 protein chimeras were generated in the pMyc3-
p110αmouse/p110βhuman plasmid (Pastor, 2004; James, 2005) which was derived from the 
pRC/CMV vector (Invitrogen). The yeast two-hybrid bait plasmid pEG202 allows the 
constitutive expression of LexA-fusion protein as well as the auxotrophic selectable marker, 
histidine. The yeast two-hybrid pJG4-5 prey plasmid allows the expression of a galactose-
induced B42-fusion protein as well as the constitutive expression of the auxotrophic selectable 
marker, tryptophan. Both plasmids were provided by Dr. Ronald Geyer (University of 
Saskatchewan). 
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3.1.6 Primers 
Table 3.2. Primers for GST-Rab5 mutagenesis and pMyc3-iSH2-p110beta mutagenesis. 
All primers were custom-ordered through Invitrogen Life Technologies. Primers were used for 
mutagenesis in sense/antisense pairs with the sense strand as indicated below with mutant 
codon underlined.  
Mutagenesis Primers 
Primer Name Sequence  
GST-Rab5 S84A CGA TAC CAT GCC CTA GCA CCA ATG 
GST-Rab5 S84L GAA CGA TAC CAT CTC CTA GCA CCA ATG 
GST-Rab5 S84E CAA GAA CGA TAC CAT GAG CTA GCA CCA ATG TAC 
GST-Rab5 S84R CAA GAA CGA TAC CAT AGG CTA GCA CCA ATG TAC 
GST-Rab5 E106A C ACA AAT GAG GCG TCC TTT GCA AG  
GST-Rab5 N113A GCA AGA GCA AAA GCT TGG GTT AAA GAA C 
GST-Rab5 N113RE GCC AGA GCC AAA TTG TGG GTT AAA GAA C 
GST-Rab5 F145A GA GCT GTC GAT GCC CAG GAA GCA C 
GST-Rab5 E172A G AAT GTA AAT GCA ATA TTC ATG G 
GST-Rab5 E172R G AAT GTA AAT CGA ATA TTC ATG GC 
GST-Rab5 M175A GAA ATA TTC GCG GCA ATA GCT 
GST-Rab5 K179A GCA ATA GCT GCA AAG TTG CCA 
GST-Rab5 K180A CA ATA GCT AAA GCG TTG CCA AAG 
GST-Rab5 
K179E+K180E 
C ATG GCA ATA GCT GAA GAG TTG CCA AAG 
GST-Rab5 Q44E GTG AAG GGC GAA TTT CAT GAA 
GST-Rab5 H46A GGC CAA TTT GCT GAA TTT CAA GAG 
  GST-Rab5 E47A GGC CAA TTT CAT GCA TTT CAA GAG AG 
GST-Rab5 I53A GAG AGT ACC GCA GGG GCT GC 
GST-Rab5 F57A CC ATT GGG GCT GCT GCT CTA ACC C 
GST-Rab5 W74A G TTT GAA ATA GCG GAT ACA GCT GG 
GST-Rab5 E80R CA GCT GGT CAA CGA CGA TAC CAT AG 
GST-Rab5 R81E GCT GGT CAA GAA GAA TAC CAT AGC C 
GST-Rab5 Y82A GGT CAA GAA CGA GCC CAT AGC CTA GC 
GST-Rab5 H83E CAA GAA CGA TAC GAG AGC CTA GCA CC 
GST-Rab5 L85A CGA TAC CAT AGC GCA GCA CCA ATG TAC 
GST-Rab5 M88A GC TTA GCA CCA GCG TAC TAC AGA GG 
GST-Rab5 Y89A C TTA GCA CCA ATG GCC TAC AGA GGA GC 
GST-Rab5 R91E CCA ATG TAC TAC GAA GGA GCA CAA GC 
p110betahuL232A C CAA AAA CGT GCG ACT ATT CAT GG 
p110betahuI234A CGT TTG ACT GCT CAT GGG AAG G 
p110betahuE238R CAT GGG AAG AGA GAT GAA GTT AGC C 
p110betahuD239R GGG AAG GAA CGT GAA GTT AGC CCC 
  p110betahuY244A   GTT AGC CCC GCT GAT TAT GTG TTG C 
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Table 3.3 Other primers. All primers were custom-ordered through Invitrogen Life 
Technologies. All sequencing primers are mentioned first, followed by special primers that 
include: the NheIGly7 primers used for the generation of the glycine linker (glycine codons 
underlined) of pMyc3-iSH2-p110, the PCR primers for the amplification of p85 iSH2 domain 
(p85 codons underlined) for pMyc3-iSH2-p110, and primers for amplification of full-length p85 
(p85 codons underlined) and full-length Rab5 (Rab5 codons underlined) for homologous 
recombination. 
 
Primer Name Sequence  
Sequencing Primers 
5′GST  TTT GCA GGG CTG GCA AGC  
5′Myc-seq  GGA TCT GCT GAG CGA GCA G 
5′pEG202 seq  GGG CTG GCG GTT GGG GTT ATT C 
5′pJG4-5 seq GGA CAG GAG ATG CCG ATG GA 
5′b110seq114 CAA GAA GTT GTG ACC CAG G 
5′b110seq272 TGT GTG ATG AAC AGA GCC C 
5′b110seq435 GCA TTA TCC TGT AGC GTG G 
5′b110seq561 TTT GCG ACA AGA CTG CCG AGA G 
5′b110seq816 GAC ACT CCA AAT GTT GCG 
3′b110seq875 GGC ATC TTT GTT GAA GGC 
5′p110seq1 ATG CCT CCA CGA CCA TCT 
5′p110seq401 CAG AAG TCC AAG ACT TTC 
5′p110seq801 AGT CAG TAC AAG TAC ATA 
5′p110seq1203 CCT TTG CCT TTC AAT CTG 
5′p110seq1604 GCA CCC GGG ACC CAC TAT 
5′p110seq2005 TGG CAT TTA AAA TCT GAG 
5′p110seq2401 TTT AAA AAT GGC GAC GAC 
5′p110seq2808 TGG GCA CTT TTT GGA TCA 
Special Primers (Linkers and PCR) 
5′NheIGly7 CT AGC GGT GGA GGA GGT GGT GGA GGT A 
3′NheIGly7 CT AGT ACC TCC ACC ACC TCC TCC ACC G  
5′NheIp85iSH2 GCA GCT AGC TTA TAT GAA GAA TAT ACC CG  
3′NheIp85iSH2 CCA GCT AGC TTT AAT GCT GTT CAT ACG TTT G  
5′BamHI-pEG202-p85 GTT ATT CGC AAC GGC GAC TGG CTG GAA TTC CCG GGG 
ATC CGT AGT GCC GAG GGG TAC CAG 
3′NotI-pEG202-p85 GGA ATT AGC TTG GCT GCA GGT CGA CTC GAG CGG CCG 
CCA TTA TCG CCT CTG CTG CGC GTA 
5′EcoRI-pJG4-5-Rab5 TAC CCT TAT GAT GTG CCA GAT TAT GCC TCT CCC GAA 
TTC GCT AGT CGA GGC GCA ACA AGA 
3′XhoI-pJG4-5-Rab5 TGA CCA AAC CTC TGG CGA AGA AGT CCA AAG CTT CTC 
GAG TTA GTT ACT ACA ACA CTG ATT 
 
37 
 
3.1.7 Other reagents and supplies 
The non-hydrolyzable GTP analogues used were GTPγS from Sigma-Aldrich and 
GppCp from Jena Bioscience. Both were obtained as a sodium salt and dissolved in ddH2O. All 
other reagents and chemicals used were purchased from Sigma-Aldrich or VWR and were of 
analytical grade or higher unless otherwise specified.  
3.2 Methods 
3.2.1 Generation of Myc3-iSH2-p110α and Myc3-iSH2-p110β 
3.2.1.1 Addition of a glycine linker 
Myc-tagged p110 (α and β) constructs were already present in the laboratory (made by 
Chris Pastor and Kristy James, respectively). Two designed primers which encode seven 
glycine residues flanked by NheI restriction site sticky ends (see Table 3.3) were used to add a 
glycine linker N-terminally to p110. Each primer (0.3 mM) was phosphorylated by 10 U of T4 
polynucleotide kinase (New England Biolabs or NEB) in the presence of 1 µM ATP, at 37°C 
for 1 hour. The T4 polynucleotide kinase was heat-inactivated by incubation at 75°C for 10 
min. The two phosphorylated primers were pooled and annealed by heating in boiling water and 
allowing them to cool slowly to room temperature. Two µg of the plasmid, pMyc3-p110 (α or β) 
was digested with 10 U of NheI (NEB) in One-Phor-all buffer (United States 
Biochemical/Affymetrix) for 1 hour at 37°C. The digested plasmid was treated with shrimp 
alkaline phosphatase (SAP; Fermentas) for 1 hour at 37°C, and then SAP was heat-inactivated 
by incubation at 75°C for 10 min. The phosphorylated annealed glycine linker oligonucleotides 
(6.66 pmol) were ligated into the SAP-treated plasmid (45 ng) using 1 µL Quick ligase (NEB) 
in 20 µL at room temperature for 20 min. The ligated DNA was transformed into TOP10 
competent cells (Hanahan et al., 1991), which were grown on LB plates with ampicillin (100 
µg/mL) selection. Plasmid DNA from the resulting colonies was isolated with QIAgen Spin 
Miniprep Kit (QIAgen) and sent to DNA Services in the Plant Biotechnology Institute for 
sequencing with the 5`Myc-seq primer (Table 3.3). The second NheI site was intentionally not 
maintained by including an imperfect sequence within the glycine linker oligonucleotides. 
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3.2.1.2 Addition of iSH2 encoding region of p85 
The region encoding the iSH2 domain of p85α was amplified from the pGEX6P1-p85α 
vector by PCR with KOD polymerase (Novagen). The primers used were specific to regions of 
p85 encoding amino acids 466 to 567 and incorporated an NheI restriction site at both ends of 
the insert (see Table 3.3, special primers). The thermocycler program used was as follows: 1) 
initial melting: 98°C for 1 min, 2) melting and annealing/extension: 20 cycles of 98°C for 15 
sec and 68°C for 10 sec, 3) final extension: 68°C for 10 sec. The amplified fragment was 
purified from the PCR reaction using a clean-up kit (QIAgen) and digested by NheI for 1 hour 
at 37°C. The digested fragment was removed from buffer and enzyme using the clean-up kit. 
The fragment was ligated into the NheI-digested and SAP-treated pMyc3-Gly7-p110 plasmids (α 
and β) using Quick ligase as before (3.2.1.1). The plasmids were sequenced using the 5`Myc-
seq primer and primers for full-length p110β or p110α (Table 3.3, sequencing primers) to 
ensure proper orientation of ligated fragments and to ensure that no mutations were added to the 
sequence during the procedure.  
3.2.2 Site-directed mutagenesis of GST-Rab5 and Myc3-iSH2-p110β 
Twenty-eight Rab5 mutations were generated within the background of pGEX6P1-Rab5 
and five p110β mutations were made in the background of pMyc3-iSH2-p110β through site-
directed mutagenesis with Pfu polymerase (Invitrogen) in a thermocycler. The reaction mixture 
contained 5 µL of the Pfu buffer (10X) with MgSO4 provided, 0.05 mM dNTPs, 10-200 ng of 
template DNA, 125 ng of each sense/antisense mutagenic primer (See Table 3.2, mutagenesis 
primers) and 2.5 U of Pfu polymerase in a 50 µL reaction volume. The program used was as 
follows: 1) initial melting: 95ºC for 30 sec, 2) melting, annealing and extension: 18 cycles of 
95ºC for 30 sec, 55ºC-67ºC (depending on the primer Tm) for 1 min and 72ºC for 11 min 15 sec 
(pGEX6P1-Rab5) or 5 min 30 sec (pMyc3-iSH2-p110β), 3) final extension: 72ºC for 5 min.  
The reaction products were digested with 10 U DpnI (New England Biolabs) for 1 hour 
at 37ºC to selectively nick the methylated parental wild-type plasmid DNA which had been 
isolated from E. coli. The samples were transformed into TOP10 competent cells, which were 
grown on LB plates with ampicillin (100 µg/mL) selection. Plasmid DNA from the resulting 
colonies was isolated with a QIAgen Spin Miniprep Kit (QIAgen) and sent to DNA Services in 
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the Plant Biotechnology Institute for sequencing with the 5`GST primer (pGEX6P1-Rab5) or 5` 
b110seq114 primer (pMyc3-iSH2-p110β) to confirm the mutation. 
3.2.3 Yeast two-hybrid analysis of LexA-p85wt and B42-Rab5wt 
3.2.3.1 PCR amplification of p85 and Rab5 encoding regions 
The full-length p85α human cDNA was amplified by PCR from pGEX6P1-p85 with 
primers encoding 42 bases of pEG202 vector DNA and 21 bases specific to p85 (see Table 3.3, 
special primers) using Pfu polymerase in a thermocycler. The program used is as follows: 1) 
initial melting: 95°C for 4 min, 2) melting, annealing and extension: 35 cycles of 95°C for 30 
sec, 80°C for 30 sec and 72°C for 5 min, 3) final extension: 72°C for 10 min. Similarly, the full-
length Rab5A human wild-type cDNA was amplified from pGEX3X-Rab5 with Rab5 specific 
primers extended by 39 bases of pJG4-5 sequence (Table 3.3, special primers).  
3.2.3.2 Homologous recombination of yeast two-hybrid plasmids and p85 or Rab5 
The full-length p85 and Rab5 inserts were incorporated into BamHI/NotI and 
EcoRI/XhoI sites of the plasmids pEG202 and pJG4-5, respectively by homologous 
recombination within the yeast cell environment. Yeast competent cells were generated through 
the Gietz and Schiestl procedure (2007) whereby a 50 mL overnight culture of a selected yeast 
colony was grown to an OD600nm of 0.6, harvested and washed with 25 mL ddH2O by 
centrifugation at 3000 x g for 5 min at 20°C. The pelleted cells were resuspended in 0.5 mL of 
100 mM lithium acetate and aliquoted into 10 x 50 µL samples.  
Both insert and plasmid DNA was transformed into yeast competent cells using the 
lithium acetate transformation procedure (Gietz and Schiestl, 2007). Briefly, a sample of 
competent cells were pelleted at 13000 x g for 15 sec and the supernatant was replaced by the 
reaction mixture containing: 260 µL of 50% (w/v) polyethylene glycol 3350, 36 µL 1 M lithium 
acetate, 50 µL of 2 mg/mL single-stranded DNA, 0.5 µg plasmid DNA and 1 µg PCR insert. 
The mixture and cells were vortexed and incubated at 30°C for 45 min, and then heat shocked 
for 20 min at 42°C. The cells were pelleted, resuspended in ddH2O and plated on auxotrophic 
selective plates SDH
-
 (pEG202) or SDW
- 
(pJG4-5) and incubated at 30°C for three days.  
The plasmids were isolated from the resulting colonies and subjected to colony PCR, 
where the extracted plasmid DNA was used as a template for the amplification of the gene of 
interest (p85 or Rab5 in this case) by KOD polymerase and primers (Table 3.3). The PCR 
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conditions were as follows: 1) initial melting: 98°C for 1 min, 2) melting, annealing and 
extension: 30 cycles of 98°C for 15 sec, 80°C for 2 sec and 72°C for 20 sec, 3) final extension: 
72°C for 5 min.  Confirmation of incorporation of the gene of interest into the plasmid was 
achieved by sequencing through the multiple cloning sites of both pEG202 and pJG4-5 using 
the sequencing primers in Table 3.3.  
3.2.3.3 Yeast two-hybrid assay for p85wt and Rab5wt interaction 
Yeast strain EY111 competent cells were transformed with the LexA-p85 bait plasmid 
using the lithium acetate transformation (Gietz and Shiestl, 2007). Similarly, the EY93 strain 
was transformed with the B42-Rab5 prey plasmid. Both strains were incubated on rich media 
plates [YPDA: 1% (w/v) yeast extract, 2% (w/v) peptone, 80 mg/L adenine and 2% (w/v) 
dextrose] at 30°C for 3 days. Colonies were isolated, lysed in 0.1 M NaOH and boiled in SDS 
sample buffer. The extracted protein was subjected to SDS-PAGE, transferred to nitrocellulose 
and probed for p85 and Rab5 expression by western blot. Those that were expressing high 
levels of either LexA-p85 (~110 kDa) or B42-Rab5 (~37 kDa) were grown in culture overnight 
and then mated on a YPDA plate. After three days at 30°C, the resulting diploid colonies were 
assessed for protein expression by immunoblotting with anti-p85 or anti-Rab5 as before. Those 
that expressed both proteins were then spotted onto selection media plates; first SDH
-
W
- 
(sugar 
source is dextrose, lacking histidine and tryptophan), SGH
-
W
-
 (sugar source is galactose, 
lacking histidine and tryptophan), then SGH
-
W
-
L
-
A
-
 (galactose, lacking histidine, tryptophan, 
leucine and adenine), SDH
-
W
-
L
-
A
-
 (dextrose, lacking histidine, tryptophan, leucine and 
adenine) and SGH
-
W
-
L
-
A
-
Xgal (galactose, lacking histidine, tryptophan, leucine and adenine 
with Xgal) to assess the expression of reporter genes (for leucine, alanine and beta-
galactosidase) driven by p85:Rab5 interaction.  
3.2.4 Expression and purification of GST-Rab5 and GST-p85 proteins 
DNA encoding GST-Rab5 or GST-p85 was transformed into protease-deficient BL21 
cells. For protein overexpression, 1 L LBA was inoculated with a 5 mL overnight culture of 
BL21 expressing GST-p85 or GST-Rab5 and grown at 37°C to an OD600nm of 0.6. Protein 
expression was induced by Isopropyl β-D-1-thiogalactopyranoside (0.3 mM, Calbiochem) at 
room temperature overnight with shaking. Cells were pelleted at 6000 x g at 4°C for 15 min and 
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resuspended on ice in 5 mL of LBA. Aliquots of 100 mL equivalents (or 1/10
th
 of the cells) 
were pelleted again; the supernatant was removed and stored at -80°C until needed. 
To purify the GST-fusion protein, an aliquot of cells was resuspended in 1 mL 
phosphate buffered saline (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4) + 
10 µg/mL aprotinin (Calbiochem), 10 µg/mL leupeptin and 1 mM AEBSF [4-(2-Aminoethyl) 
benzenesulfonyl fluoride]. Lysis of cells was achieved by incubation with 1 mg/mL lysozyme 
on ice of 30 min and sonication (3 x 10 seconds at setting 1.5). After sonication, a 10 min 
incubation with DNase (100 U, room temp) was performed to reduce viscosity. Triton X-100 
(to 1%) was added to the tubes and then the cell debris was pelleted in a microcentrifuge for 10 
min at 16100 x g at 4°C. The supernatant containing the fusion protein was passed through a 
0.45 µM filter (Nalgene) to remove additional cell debris and contaminants. Glutathione-
Sepharose beads (Amersham) (100 µL of a 50% suspension) were added to the filtered lysate 
and allowed to bind at 4°C for 1 hour. The beads were pelleted by centrifugation (2300 x g, 1 
min) and washed three times with 500 µL PBS, before being resuspended (50 µL beads) in 450 
µL of PBS.  
Protein concentration of a 10 µL aliquot of beads was determined by boiling the beads 
for 5 min in sodium dodecyl sulfate (SDS) sample buffer [10% (w/v) glycerol, 5% (v/v) 2-
mercaptoethanol, 2.3% (w/v) SDS, 0.0625 M Tris, pH 6.8, 0.02 mg/mL bromophenol blue] for 
5 min, pelleting the beads, and performing a Lowry assay (Sigma-Aldrich) on the supernatant 
containing the fusion protein. 
Purification of p85 protein from GST-p85 bound to glutathione-Sepharose beads was 
achieved using 3C Prescission protease. In this case, the entire volume of culture (1 L) was 
lysed at once. The filtered lysate was added to 2 mL of a 50% suspension of glutathione-
Sepharose beads and incubated for 1 hour at 4°C. The beads were pelleted and washed 5 times 
in Prescission Lysis Buffer [(PLB): 50 mM Tris-HCl pH 7.0, 150 mM NaCl, 1 mM 
Ethylenediaminetetraacetic acid (EDTA)]. The 3C Prescission protease (100 μL in 900 μL 
PLB) was added to the beads and allowed to cleave the protein overnight at 4°C with agitation. 
The beads were pelleted and the supernatant containing the cleaved protein was collected. 
Washes with PLB were performed until the OD280nm was less than 0.2. All washes containing 
p85 protein were pooled.  
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3.2.5 Protein visualization 
3.2.5.1 Coomassie blue staining 
Proteins were resolved by  sodium dodecyl sulfate polyacrylamide gel electrophoresis  
(SDS-PAGE, 7.5-15% acrylamide, EM Science) (Laemmli, 1970) and Coomassie blue staining 
[0.14% (w/v) Coomassie Blue R-250 (Bio-Rad), 41.4% (v/v) methanol, and 5.4% acetic acid]. 
Unbound Coomassie blue was removed by washing gels with destain solution [41.4% (v/v) 
methanol, 5.4% (v/v) acetic acid]. A single band of 50 kDa was expected for GST-Rab5 fusion 
proteins and additional bands were considered contamination from other cellular proteins or 
proteolytic products of GST-Rab5. For p85 purified as GST-p85 and cleaved with 3C 
Prescission protease, a single band of ~85 kDa was expected. 
3.2.5.2 Western blotting 
 For western blot analysis (immunoblot), proteins resolved by SDS-PAGE were 
transferred to a nitrocellulose membrane (Whatman) in transfer buffer [48 mM Tris-HCl pH 
9.2, 0.038% (w/v) SDS, and 20% (v/v) methanol) using an Owl Panter Semi-Dry Electroblotter 
(VWR). The apparatus was layered as follows: three pieces of 3MM filter paper (Whatman) 
pre-soaked in transfer buffer, SDS-PAGE gel, one nitrocellulose membrane pre-hydrated in 
H2O, three more pre-soaked 3MM filter papers. Any air bubbles between the layers were 
removed by rolling a tube over the layers. A constant current of 400 mA was applied to transfer 
proteins from the gel to the nitrocellulose for 15 min/gel. 
The nitrocellulose membrane (blot) was incubated in blocking solution [5% (w/v) 
Carnation skim milk powder (Safeway) in PBS] for 1 hour at room temperature while rocking. 
The blot was incubated with 5 mL primary antibody solution for 1 hour at room temperature. 
The blot was washed three times for 5 minutes in PBS. The appropriate secondary antibody 
(anti-mouse for FLAG and p85 blots, anti-rabbit for Myc blots) was prepared in 5 mL blocking 
solution. The blot was incubated with secondary antibody for 1 hour at room temperature. The 
blot was washed as before and scanned using the LI-COR Odyssey Infrared Imager (LI-COR 
Biosciences) and analyzed with the Odyssey V3.0 software and Microsoft Excel. 
43 
 
3.2.5.3 Protein visualization software  
 To visualize the orientation of Rab5 amino acid side chains of the GDP-bound crystal 
structure in comparison to the GTP-bound structure, the program Protein Workshop was used 
(Moreland et al., 2005). Figures 4.3, 4.10, and 4.12 were generated with this software using the 
crystal structure information deposited in the Protein Data Bank (www.rcsb.org) for Rab5-GDP 
(PDB ID: 1TU4) and Rab5-GNP (PDB ID: 1R2Q). 
The structural alignments of proteins in Table 3.4 were generated using the program 
PyMOL (The PyMOL Molecular Graphics System, Version 1.4.1 Schrödinger, LLC.).  
Table 3.4 Protein data used in structural alignments.  
Figure Protein A (PDB ID) Aligned with Protein B and C (PDB ID) 
1.2 Ras-GDP (SP21) - 
1.2 Ras-GNP (4Q21) - 
1.5 REP1:Rab7 (1VG0) RabGGTase:REP1 (1LTX) 
1.5 RabGDI:Ypt1 (2BCG) - 
1.9 Ras:p120rasGAP (1WQ1) - 
1.9 Rho:p50rhoGAP (1TX4) - 
4.14 p110β:ci-p85β (2Y3A) p110α:ni-p85α (3H1Z) 
5.2 Cdc42:p50rhoGAP (1AM4) Rab5-GNP (1R2Q) and p85 BH domain (1PBW) 
5.2 Rho:p50rhoGAP (1TX4) Rab5-GNP (1R2Q) and p85 BH domain (1PBW) 
5.3 Cdc42:p50rhoGAP (1AM4) p85 BH domain (1PBW) 
5.3 Rho:p50rhoGAP (1TX4) p85 BH domain (1PBW) 
5.4 Ras:p110γ (1HE8) Rab5-GNP (1R2Q) and p110β:ci-p85β (2Y3A) 
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3.2.6 Mammalian cell culture 
COS-1 cells were grown in Dulbecco's Modified Eagle Medium (DMEM; Gibco) 
supplemented with 10% fetal bovine serum (FBS; Gibco) at 37°C + 5% CO2.  
3.2.6.1 COS-1 lipofectamine transfection 
 Transfection of COS-1 cells was performed at 40% confluency, as determined visually 
by light microscopy. Lipofectamine (18 µL; Invitrogen) and DNA (6 µg) were added to 
separate 600 µL samples of OPTI-MEM (Gibco) and then mixed together and incubated for 15 
min at room temperature. Cells were washed with serum-free DMEM prior to transfection. The 
OPTI-MEM solution with DNA and lipofectamine was diluted by the addition of 4.8 mL of 
serum-free DMEM and added to cells. Transfection media remained on cells for 5 hours at 
37°C + 5% CO2. After 5 hours, 6 mL of DMEM + 20% FBS were added and the cells were 
grown overnight at 37°C + 5% CO2. The media was changed to DMEM + 10% FBS and the 
cells were grown for an additional 48 hours. 
3.2.6.2 Cell lysis procedure 
Cells were placed on ice and washed with PBS. One mL of cell lysis buffer (50 mM 
HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EDTA, 
10 mM NaPPi, 100 mM NaF, + 10 µg/mL aprotinin, 10 µg/mL leupeptin and 1 mM AEBSF) 
was used to induce cell lysis for 5 mins. Plates were scraped with a spatula to remove all cells 
and transferred to Eppendorf tubes. Cell lysate was centrifuged at 16100 x g for 10 min at 4°C, 
to pellet cell debris. Supernatant was stored at -80°C until needed.  
Total protein concentration was determined by Lowry assay of 25 µL aliquots. The 
presence of overexpressed protein of interest was observed by western blotting for either the 
FLAG/Myc tag or the protein itself, in the case of p85. For Myc3-iSH2-p110β mutants, pull-
down experiments required consistent protein concentration between mutant and wild-type 
lysates. Therefore, 10 µL of each Myc3-iSH2-p110β (wt and mutant) lysate was subjected 
western blotting and their intensities were quantified as arbitrary units using Odyssey software 
V3.0 and Microsoft Excel. Normalization of relative expression to Myc3-iSH2-p110βwt as well 
as total protein concentration required the dilution of some Myc3-iSH2-p110β mutant lysates 
with untransfected COS-1 lysate.  
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3.2.7 Pull-down binding assay using immobilized GST-Rab5 (wt or mutant) and p85 or 
FLAG-p85 or Myc3-iSH2-p110 
Ten µg of GST-Rab5 protein already attached to beads was stripped of nucleotide by 
incubation for 30 min at room temperature with buffer containing EDTA [20 mM Tris-HCl pH 
7.5, 50 mM NaCl, 1 mM dithiothritol (DTT), 5% glycerol, 0.1% Triton X-100, 10 mM EDTA 
pH 8.0, 10 µg/mL aprotinin, 10 µg/mL leupeptin], which chelates the Mg
2+
 ion necessary for 
proper nucleotide binding. Beads were pelleted and the supernatant was aspirated. The desired 
nucleotide, e.g. GDP, GTPγS or GppCp, was added (200 nM) to the beads in nucleotide loading 
buffer containing Mg
2+
 (20 mM Tris-HCl pH 7.5, 50 mM NaCl, 1 mM DTT, 5% glycerol, 0.1% 
Triton X-100, 10 mM MgCl2, 10 µg/mL aprotinin, 10 µg/mL leupeptin) and incubated at room 
temperature for 30 minutes. Beads were pelleted and the supernatant was aspirated. The beads 
were then incubated for 30 min either with 25 µL FLAG-p85 cell lysate, diluted in 75 µL 
nucleotide loading buffer, or with normalized Myc3-iSH2-p110 cell lysate in nucleotide loading 
buffer to a total protein concentration of 130 µg and total volume of 500 µL. The beads were 
washed 4 times with 400 µL 1% Nonidet P-40 buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% 
Nonidet P-40) and bound proteins were eluted in SDS sample buffer. The protein containing 
buffer was subjected to SDS-PAGE and immunoblot assay to detect bound FLAG-p85 (FLAG), 
p85 (p85) or Myc3-iSH2-p110 (Myc).  
Purified p85 protein pull-down assays required a blocking step after nucleotide binding. 
The nucleotide loading buffer with 10% bovine serum albumin (BSA) and 10% skim milk 
powder (Carnation, Safeway) added was used for this step. Beads were incubated with the 
blocking solution for half an hour before addition of p85, and the blocking solution was not 
removed during the p85 incubation step. Purified p85 was added to a final concentration of 37.5 
ng/µL (in PLB).  
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3.2.7.1 Statistical evaluation of data 
 Blots were scanned directly using the LI-COR Odyssey Infrared Imager (LI-COR 
Biosciences). The bands visualized using Odyssey software V3.0 were quantified and given 
arbitrary intensity units using Microsoft Excel. Background intensity or GST negative control 
lane intensity, when relevant, was subtracted from all sample bands. Protein expression in 
Myc3-iSH2-p110-expressing cell lysates was normalized to the wild type protein, which was 
assigned a value of 1. The amount of FLAG-p85, p85wt or Myc3-iSH2-p110β bound to GST-
Rab5 fusion proteins in each pull-down experiment was normalized to either wild-type Rab5-
GTPγS (100%) or Rab5wt-GDP (100%) depending on bound nucleotide. Data from three or 
more independent experiments were combined as mean ± SD, as indicated in each figure 
legend. P-values to assess statistically significant differences were obtained using Prism 
software (GraphPad Prism 4.00, San Diego, CA) using a one-way ANOVA and Dunnett’s 
multiple comparison test.   
3.2.9 Co-immunoprecipitation analysis of FLAG-p85 and Myc3-p110 or Myc3-iSH2-p110 
COS-1 cells were cultured and co-transfected with FLAG-p85 and Myc3-p110 or Myc3-
iSH2-p110 as described in section 3.2.6.1. Cells were lysed in 1 mL cell lysis buffer (see 
section 3.2.6.2) and centrifuged for 10 min at 16100 x g. The entire lysate was precleared of 
non-specific binding proteins using agarose conjugated (AC) mouse IgG antibodies (Table 3.1) 
and protein A Sepharose beads (10 µg) for 1 hour at 4°C with rocking. The antibodies were 
pelleted at 4°C, 16100 x g and the supernatant divided into two samples. The precleared lysate 
samples were incubated with protein A Sepharose beads (10 µg) and either AC Myc antibody 
or AC mouse IgG antibody for 1 hour at 4°C with rocking. The beads with bound antibodies 
and associated proteins were pelleted at low speed (500 x g) for 2 min and washed three times 
with 1 mL 1% Nonidet P-40 buffer. The samples were resolved on two SDS-PAGE gels and 
both were subjected to western blot analysis. One blot was probed for Myc3-p110 or Myc3-
iSH2-p110 with anti-Myc antibody; the other was probed for p85 with anti-p85 antibody.  
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4.0 RESULTS 
4.1 Pull-down experiments with Rab5, Rab4 and Rab11 and p85 
 Previous work had shown that p85 has GAP activity towards Rab5 and Rab4, but it has 
no GAP activity towards Rab11 (Chamberlain et al., 2004). GAP function involves the 
insertion of an arginine finger into the nucleotide binding site of the Rab protein. Interestingly, 
p85 bound to both active and inactive forms of Rab5 (Chamberlain et al., 2004). This suggested 
that the binding site for p85 on the Rab5 protein is likely to be outside of the switch regions of 
Rab5 that remain in similar conformations for both Rab5-GDP and Rab5-GTP. Being members 
of the same superfamily of Rab GTPases, Rab5, Rab4 and Rab11 have very strong sequence 
identity. Therefore to investigate p85 binding, a pull-down experiment was performed with p85 
and each of Rab5, Rab4 and Rab11 in both active and inactive forms. It was hypothesized that, 
because p85 was a poor GAP towards Rab11, binding between the two proteins would be very 
low.  
 Each of Rab5A, Rab4 and Rab11 was generated as a GST-fusion protein, overexpressed 
in BL21 E. coli cells and purified by binding to glutathione-Sepharose beads. To discriminate 
between GDP- and GTP-bound conformations of the Rab proteins, and their effects on binding 
to p85, each Rab was stripped of bound nucleotide by incubation with an EDTA-containing 
buffer, as described previously (Hart et al., 1994) followed by reloading the nucleotide binding 
site of the Rab with either GDP or a non-hydrolysable GTP-analogue, GTPγS, in a Mg2+-
containing buffer. This method, which does not ensure 100% of desired GDP- or GTP-bound 
Rab, can at least provide a majority of the desired conformation to allow discrimination 
between the two in the pull-down assays performed in this thesis.  
 The p85 used in the binding experiments was provided by COS-1 (green monkey 
kidney) cell lysate transiently expressing exogenous FLAG-tagged p85. The use of cell lysate 
for binding studies allowed for other cellular proteins to compete for binding to the purified Rab 
proteins. Endogenous p85 was also expressed, but at a much lower concentration, and could 
also compete for Rab5 binding. The FLAG-p85 lysate was added to the GST-Rab protein beads 
after loading with nucleotide and was allowed to bind for 30 minutes. The samples were then 
washed three times with 1% Nonidet P-40 containing buffer, subjected to SDS-PAGE and 
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transferred to a nitrocellulose membrane. The resulting blots were probed with anti-FLAG 
antibody, so endogenous p85 binding was not considered.  
 The binding of FLAG-p85 to Rab4 and Rab11 was less than Rab5 (Figure 4.1). 
Specifically, Rab4 showed nearly half as much FLAG-p85 binding as compared to Rab5, 
though there was some variability in the assay (Figure 4.1 B, see SD) The reduction in FLAG-
p85 binding to Rab4 compared to Rab5 was unexpected because the GAP activity of p85 was 
nearly equal towards both proteins (Chamberlain et al., 2004). As expected by the lack of GAP 
activity of p85 towards Rab11, little or no binding was observed between the proteins in vitro 
(Figure 4.1 A and B).  With an average binding intensity that was 7% of Rab5wt-GDP and 1% 
of Rab5wt-GTPγS, the data demonstrates that Rab11 is a not a likely binding partner for p85.  
 Pull-down assays using purified p85wt were also performed (Figure 4.1 A, lower). The 
addition of unrelated proteins (BSA, skim milk casein and whey proteins) was utilized as a 
“blocking step” to control for non-specific interaction with purified p85. The amount of p85 
binding to Rab4 was even less in these experiments compared to Rab5 binding in both 
activation states. Purified p85 showed little to no binding to Rab11 in its inactive state, whereas 
it bound to Rab11-GTPγS at similar levels to that of Rab4-GTPγS. The reproducibility of these 
results was very low using purified p85, and since more steps were required to make the 
purified protein, FLAG-p85 from cell lysates was used for the rest of the p85 binding studies. 
These Rab binding data became the basis for my mutational analysis of the binding site on 
Rab5 for p85.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
4.2 Sequence alignment between Rab5, Rab4 and Rab11 
 The amino acid sequence of human Rab5A (NP_004153.2) was aligned to both human 
Rab4 (NP_004569.2) and human Rab11 (NP_004654.1) using ClustalW (v1.83) to identify 
residues that may be involved in p85 binding (Figure 4.2). Theoretically, because Rab5 and 
Rab4 both bind to p85, they should both present a p85 binding motif on their structures, 
whereas Rab11, which does not bind to p85, should not have the binding site. Amino acids 
were selected based on their conservation between the p85 binding Rabs and the presence of 
non-conservative residues in the equivalent position of the Rab11 sequence. This first set of 
selected residues was then subjected to additional criteria, including surface accessibility and 
conservation of orientation in the GDP- and GNP- bound Rab5 crystal structures (Figure 4.3).  
Figure 4.1 FLAG-p85 binding to GST- Rab5, Rab4 but not Rab11.  A. Pull-down assay where 
10 µg of GST, GST-Rab5, GST-Rab4 or GST-Rab11 were immobilized on glutathione Sepharose 
beads and loaded with either GDP or GTPγS. Samples were incubated with FLAG-p85 expressing 
COS-1 cell lysates or purified p85 protein, as indicated, for 30 min and then washed. Samples were 
subjected to SDS-PAGE and protein was transferred to a nitrocellulose membrane. Bound p85 was 
detected with an anti-FLAG antibody (upper) or an anti-p85 antibody (lower). An infrared dye 
conjugated secondary antibody was used for visualization of bands using the LI-COR Odyssey 
scanner and software (V3.0). B. Quantification of bound p85 from three separate experiments as 
performed in A. Intensity measured in arbitrary units, GST band was subtracted from each lane and 
all bands were normalized to Rab5. Mean +/- SD. (#) P < 0.05; (*) P < 0.01, based on the results of 
four separate one-way ANOVAs (FLAG-p85 GDP: F = 10.89, degrees of freedom = 8; FLAG-85 
GTPγS: F = 9.252, df = 8; purified p85 GDP: F = 25.48, df = 7; purified p85 GTPγS: F = 13,71, df 
= 8), Dunnett’s multiple comparison test. 
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Figure 4.2 Amino acid sequence alignment of Rab5, Rab4 and Rab11. The sequence alignment 
was generated in ClustalW (v.1.83) with human Rab5 (NP_004153.2), Rab4 (NP_004569.2), and 
Rab11 (NP_004654.1). Conserved residues are shaded in grey. Curved arrows indicate the limits of 
the sequence included in the crystal structure of Rab5. Switch I is labelled in purple and switch II in 
red. Q79, which catalyzes the intrinsic hydrolysis of GTP, is indicated in orange. Amino acids 
circled in blue were chosen for site-directed mutagenesis and pull-down assays with p85 based on 
the conservation between Rab5 and Rab4, but not Rab11. Teal and green stars indicate amino acids 
mutated for disruption of p110β binding.  
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Figure 4.3 Residues that may bind p85 on crystal structures of Rab5 in both GDP and GNP 
bound conformations. Structures of Rab5-GDP (PDB ID: 1TU4) A, C and Rab5 bound to GNP (a 
non-hydrolysable GTP analogue; see Figure 1.8 for structure) (PDB ID: 1R2Q) B, D with 
highlighted blue residues selected for mutation to disrupt p85 binding based on their conservation 
between Rab5 and Rab4 sequences but not in Rab11. Site A Rab5 mutation residues are shown in 
panels A and B, whereas site B mutation residues are shown in panels C and D. Conventional 
numbering of alpha-helices is indicated. Images generated in Protein Workshop (Moreland et al., 
2005).   
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 The crystal structure has been solved for Rab5 in its GDP- bound inactive state as well 
as Rab5 bound to non-hydrolysable GTP analogues and transition state analogues (Zhu et al., 
2003; Terzyan et al., 2004; Zhu et al., 2004; Eathiraj et al., 2005). These crystals were derived 
from a modified Rab5 protein lacking its very N- and C-terminal residues. The 14 N-terminal 
residues and residues 186-215 of the C terminus were therefore eliminated from our analysis 
(Figure 4.2, curved arrows) since it was not clear where they would be positioned in the folded 
Rab5 structure. The putative p85-binding residues from the sequence alignment were located on 
the crystal structure of Rab5 (PDB ID: 1TU4 and 1R2Q) and assessed for accessibility for 
binding and conservation of orientation between active and inactive structures (Figure 4.3).  
 The eight amino acids that fulfill these criteria were as follows: S84, E106, N113, F145, 
E172, M175, K179 and K180. Although S84 was within the switch II region, it was also 
selected for mutation based on its sequence conservation between Rab5 and Rab4 and 
divergence with the Rab11 sequence. It was noted that the residues were found clustered on two 
faces of the crystal structure of Rab5, therefore two putative “binding sites” were tested, site A 
and site B. Residues were assigned to either site A or B depending on which face of Rab5 they 
resided (Figure 4.3 A and B vs. C and D). A list of all mutations made to Rab5 can be found in 
Table 4.1.  
4.3 Pull-down experiments with FLAG-p85 and Rab5 mutants 
4.3.1 Rab5 site A mutant binding studies 
 The amino acids of Rab5 site A included S84, E106, and N113. Mutation of individual 
residues to alanine can be used to assess their involvement in the binding site between two 
proteins, but only when the side chain of that amino acid is involved in forming contacts with 
the binding partner. It would not be useful, in this case, if p85 is interacting with the backbone 
of any of the chosen Rab5 amino acids, nor if their binding is influenced by many residues 
providing small forces. Charge reversal or hydrogen bond disrupting mutations can sometimes 
provide enough repulsive force to reduce or inhibit binding even though many other residues 
are also involved in the interaction. According to this rationale, the identified residues of Rab5 
were mutated to alanine and, in the case of N113, to glutamic acid for a more drastic change in 
amino acid structure and charge. 
 
p85 binding p85 binding p110β 
binding 
p110β  
binding 
p110β  
binding 
Site A Site B Switch I Switch II Effector 
binding 
S84A F145A Q44E E80R I53A 
E106A E172A H46A R81E F57A 
N113A E172R E47A W74A 
N113E M175A (Y82A) Y82A 
K179A H83E 
K180A S84A 
K179+180E (L85A) L85A 
(M88A) M88A 
(Y89A) Y89A 
(R91E) R91E 
Table 4.1  Mutations of Rab5 amino acids based on sequence alignment. Putative p85 binding 
site A consisted of amino acids identified as conserved between Rab5 and Rab4 but different in 
Rab11, and having similar conformations in the crystal structure of both GDP- and GTP-bound 
Rab5, which were outward facing on the “front” face (according to Figure 4.3). Mutations to 
alanine or a residue of opposite charge are indicated. Putative p85 binding site B residues were 
chosen using the same criteria and are found on the opposite face of Rab5 to site A. Binding to 
p110β was assessed with Rab5 mutations of amino acids within the switch regions that have large 
conformational differences between GDP and GTP bound structures of Rab5, and that do not affect 
nucleotide binding. Additional mutations were made to amino acids important in binding Rab5 
effectors EEA-1 and Rabenosyn-5, many of which are found in the switch II region.  
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Figure 4.4 No reduction in FLAG-p85 binding to Rab5  site A mutants. A. GST, GST-Rab5 wt 
and mutant (as indicated) fusion proteins (10 µg) immobilized on glutathione Sepharose beads were 
loaded with either GDP or GTPγS and incubated with FLAG-tagged p85 from transfected COS-1 
lysate. Bound p85 was detected using an immunoblot analysis with an anti-FLAG antibody. B. 
Quantification of pull-down binding data (n=3), intensity measured in arbitrary units and 
normalized to Rab5-wt; mean  SD. Statistical analysis of GDP-bound Rab5 and mutants: one way 
ANOVA (F = 4, df = 17); GTPγS one-way ANOVA (F = 14.13, df = 17), (*) P <0.01, Dunett’s 
multiple comparison test. Only statistically significant P values are indicated. C. Pull-down 
immunoblot results of GST-Rab5, wt and mutants (as indicated), fusion proteins loaded with either 
GDP or GTPγS and binding carried out as in A. 
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Figure 4.5 No reduction in FLAG-p85 binding to Rab5  site B mutants. A. GST, GST-Rab5 wt 
and mutant (as indicated) fusion proteins (10 µg) immobilized on glutathione Sepharose beads were 
loaded with either GDP or GTPγS and incubated with FLAG-p85 from transfected COS-1 lysate. 
Bound FLAG-p85 was detected using an immunoblot analysis with an anti-FLAG antibody. B. 
Quantification of pull-down binding data (n=3), intensity measured in arbitrary units and 
normalized to Rab5wt; mean  SD. Rab5-E172R-GTPγS is shown at 0.1x (red) so that the error bar 
is visible on the graph (actual value is 2382%). Statistical analysis: GDP one-way ANOVA 
(F=19.75, df=23); GTPγS one-way ANOVA (F=611.3, df=23), P<0.05 (#), P<0.01 (*), Dunett’s 
multiple comparison test. Only statistically significant P values are indicated.  
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4.4 Yeast two-hybrid experiment 
 There was inconsistency in the data obtained from the pull-down experiments. It was 
suggested that a yeast two-hybrid assay might provide more clear results. Yeast two hybrid 
experiments use the binding of two proteins of interest to bring the GAL4 transcription 
activation domain (B42) and the DNA binding domain (LexA) together to initiate the 
transcription of reporter genes (see Figure 4.6). A library of B42-Rab5 fusion protein random 
mutants was to be screened for the ability to bind p85 by mating with yeast expressing the 
LexA-p85wt fusion protein. Any colonies unable to grow on selection media plates would 
therefore be traced back to the original B42-Rab5 yeast colony and sequenced. It was 
considered an unbiased way to identify amino acids on Rab5 important in binding p85.   
 For the wild-type experiment, Rab5A human cDNA was inserted into the yeast prey 
vector by homologous recombination. The prey vector was induced by galactose and encodes a 
B42 transcription activation domain fusion protein and a nuclear localization signal (Figure 
4.6).  The p85 human cDNA was similarly inserted into the yeast bait vector which encodes for 
a LexA-fusion protein (containing the DNA-binding domain). The bait and prey vectors were 
transfected into two different strains of yeast: EY111 and EY93, respectively. The two strains 
were mated on YPDA non-selective plate and then assessed for protein expression after growth 
in galactose-containing liquid media. Both LexA-p85 and B42-Rab5 (inducible) were being 
expressed (data not shown).  
 The selection media lacked essential amino acids that the yeast could not synthesize: 
histidine (H
-
), tryptophan (W
-
), or the genes under control of the GAL4 promoter: leucine (L
-
), 
adenine (A
-
) and beta-galactosidase. Growth in (HW)
-
 media and plates suggests that both 
vectors are present in the cell because they confer the ability to synthesize histidine (bait vector) 
and tryptophan (prey vector). Growth in L
-
 or A
-
 or both (LA)
-
 media suggests that the B42 
activation domain fusion protein was brought into proximity with the LexA-fusion protein due 
to Rab5:p85 binding and drove the expression of the leucine and/or adenine synthesis genes. 
When the cells were grown in SG(HWLA)
-
 liquid media the cells grew, but when they were 
plated on the same media no colonies grew. The additional selection of Xgal + plates is the 
most stringent and growth on these plates suggests that the protein interaction is very strong. 
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Figure 4.6 Yeast two-hybrid experimental design. A. Vector maps of the B42-Rab5 “prey” 
vector (left) which encodes a galactose induced  B42 activation domain fusion protein with an N-
terminal nuclear localization signal and the TRP1 gene which enables the yeast to grow in 
tryptophan-free media and the LexA-p85 “bait” vector (right) which encodes a LexA DNA binding 
domain fusion protein and the HIS3 gene which confers the ability to grow on histidine-free media. 
B. Mechanism of protein binding selection: the transcription of leucine, adenine and β-
galactosidase genes is controlled by the GAL4 promoter and occurs when LexA-p85 and B42-Rab5 
are brought together through the binding of  their fusion proteins, p85 and Rab5 in this case.  
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The cells did not grow on any of the binding selection plates. The binding between Rab5 and 
p85 was not stable enough for the cells to endure the selection media. Therefore, this approach 
was not pursued any further. 
4.5 Identification of p110β binding surface on Rab5 
4.5.1 Generation of p110 for binding studies 
 Previous studies had shown that p110β, but not p110α, bound specifically to Rab5-
GTPγS, but not Rab5-GDP (Christoforidis et al., 1999). In this objective, the p110β binding site 
on Rab5 was to be determined. The identification of the p110β binding site on Rab5 required a 
source of stable p110 protein. This stable p110 must also be free of bound p85. In cells p110 is 
constitutively bound to p85 (Geering et al., 2007), whose interaction prevents the protein from 
being degraded (Yu et al., 1998). However, since p85 also binds to Rab5, its presence in the 
binding experiments with p110 would confuse the results.  
 A construct given to our lab from L.T. Williams, which encoded full-length cDNA of 
p110α attached at its N-terminus by a 7 glycine linker to the iSH2 domain of p85 (Figure 4.7 A, 
upper), was considered for expression of stabilized p110. There was also a C-terminal Myc tag 
for easy detection because there are few good p110 antibodies. The L.T Williams lab had 
shown previously that this protein chimera is constitutively active because it lacks the inhibitory 
contacts from p85 yet retains the stabilizing iSH2 (p85)-ABD (p110) contacts (Hu et al., 1995). 
Expression of this construct in COS-1 cells was not detectable with the suggested antibodies, 
nor with several other anti-Myc antibodies tested (data not shown). Therefore, two similar 
constructs were generated which contained a total of three N-terminal Myc tags for better 
detection, the p85 iSH2 domain (amino acids 466-567) linked via a 7 glycine linker to p110α or 
p110β (Figure 4.7 A, lower). The synthesis of the two constructs required multiple rounds of 
subcloning and sequencing because the cohesive ends of the inserts could be incorporated in 
two orientations (see Figure 4.7 B). Both chimeric proteins expressed well in COS-1 cells and 
were readily detectable by immunoblotting (Figure 4.8).  
 
Figure 4.7 Construction of p110α and p110β proteins which do not bind p85. A. Comparison 
of our construct (lower) to the one made by L.T. Williams in 1995 (upper). Numbers indicate 
amino acids. ABD, adaptor binding domain; iSH2, inter-SH2 domain from p85 which binds p110. 
B.  Diagram of  the steps to build construct from A: 1. Insert linkers encoding a 7 glycine residue 
peptide into NheI site of pMyc3p110 vectors previously made in the lab for both p110β and p110α. 
2. Sequence construct DNA with 5`Myc sequencing primer and selection of clone with appropriate 
orientation of glycine linker sequence. 3. Amplify region encoding the iSH2 domain from p85 
cDNA by PCR. 4. Insert region encoding iSH2 domain into the same NheI site of the plasmid. 5. 
Sequence construct again, to ensure correct orientation of iSH2-encoding region and through entire 
gene of p110. 
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Figure 4.8 Chimeric Myc3-iSH2-p110α/β proteins do not bind well to p85 in vivo. COS-1 cells 
were co-transfected with FLAG-p85 and Myc-p110 or Myc-iSH2-p110 constructs, as indicated, 
and lysed. Cell lysate was pre-cleared with agarose-conjugated (AC) mouse IgG antibody. The 
unbound supernatant was incubated with  either AC anti-Myc antibody or AC mouse IgG antibody 
(control). The beads with bound antibody and associated proteins were washed and samples were 
boiled in SDS to remove protein from beads. Samples were subjected to SDS-PAGE. Resulting 
gels were transferred to nitrocellulose and co-immunoprecipitation of FLAG-p85 and endogenous 
p85 with Myc-p110 or Myc3-iSH2-p110 was assessed by immunoblotting with anti-p85 and anti-
Myc antibodies as indicated. Loading pattern was as follows: 2% input lysate, ½ volume of control 
mouse IgG IP, 2% Myc IP (probed for Myc); and 2% input lysate, ½ volume control IP, 98% Myc 
IP (probed for p85). Typical result shown for one of three independent experiments.   
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4.5.2 Co-immunoprecipitation of Myc3-iSH2-p110 proteins with p85 
 It was hypothesized that the iSH2 domain within the construct would saturate the 
binding site for p85 on p110, thus isolating p110 from the endogenously expressed p85 in cell 
lysates. To test this hypothesis, a Myc immunoprecipitation was performed and the resulting 
blot was probed with p85 antibodies and Myc antibodies as a control (Figure 4.8). Both 
endogenous p85 and exogenous FLAG-p85 were expressed in COS-1 cells along with either 
Myc3-p110 (alpha or beta) or Myc3-iSH2-p110 (alpha or beta). The cells expressing the normal 
Myc-p110 protein were found to be in complex with both p85 and FLAG-p85 (Figure 4.8 A 
and C). The p110α iSH2-containing construct, however, showed little or no binding to FLAG-
p85 and greatly reduced binding to endogenous p85 (Figure 4.8 B). Myc3-iSH2-p110β showed 
the reverse: little or no binding to endogenous p85 and greatly reduced FLAG-p85 binding 
(Figure 4.8 D). These results illustrate that Myc3-iSH2-p110β can be expressed in mammalian 
cells and does not require endogenous p85 binding for stability. Therefore the constructs were a 
good source of p110β and control p110α for binding to Rab5 mutants in vitro. 
4.5.3 Pull-down experiments with Myc3-iSH2-p110 and Rab5 mutants 
 The initial wild-type binding experiments were performed with four Rab5 controls: 
Rab5wt-GDP, Rab5wt-GppCp, Rab5 GTPase-deficient mutant Q79L and dominant negative 
mutant S34N. It was found that only Rab5-GppCp was able to bind significant amounts of the 
Myc3-iSH2-p110β protein (Figure 4.9). It was expected that Rab5-Q79L-GppCp would bind to 
Myc3-iSH2-p110β because it was locked in the GTP-bound conformation, but it was later 
determined that the residue Q79 was part of the binding site for p110β on Rab5; therefore its 
mutation reduced binding. The Myc3-iSH2-p110α protein showed little or no binding to any 
form of Rab5, consistent with previous published work (Christoforidis et al., 1999). These 
results indicated that Myc3-iSH2-p110β bound specifically to Rab5-GppCp and was suitable for 
experiments to test p110β binding to Rab5 mutants. 
 
Figure 4.9 Rab5-GTP binds to Myc3-iSH2-p110β but not Myc3-iSH2-p110α. pull-down assay 
where GST, GST-Rab5wt  bound to GDP or GppCp (a non-hydrolysable analogue of GTP), GST-
Rab5-S34N (a mutant locked in the inactive conformation), or GST-Rab5-Q79L (active 
conformation mutant) were incubated with  a chimeric Myc3-iSH2-p110α or Myc3-iSH2-p110β 
protein (which contains the iSH2 domain of p85) from COS-1 lysate. pull-down analyses were 
carried out as in Figure 4.1 and were immunoblotted with anti-Myc antibodies to detect bound 
Myc3-iSH2-p110 proteins. 
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 Amino acids in the Rab5 switch regions were chosen for mutation and testing for 
binding with p110β based on their accessibility in the GNP (a non-hydrolysable GTP-
analogue)-bound crystal structure and their different conformation in the GDP crystal (Figure 
4.10). The residues originally to be characterized were Q44, H46, and E47 in switch I and E80, 
R81, H83 and S84 in switch II. Some were mutated to alanine and others to a residue of 
opposite charge (see Table 4.1). Many of the pull-down experiments were conducted alongside 
Myc3-iSH2-p110α as a negative control, but after three experiments it was decided that there 
was no binding to Myc3-iSH2-p110α with any of the Rab5 mutants, and the experiments 
continued with the GST beads and the Rab5wt-GDP as negative controls. 
 Mutations in the switch I region, Q44E and H46A did not significantly affect p110β 
binding to Rab5 (Figure 4.11). The E47A mutant showed a slight reduction in binding. The 
E80R and H83E mutations of Rab5 were promising candidates of the p110β interaction-site, as 
they significantly reduced binding with p110β (Figure 4.11, 4.12 and Table 4.2), and showed 
little or no binding to p110α (not shown). However, it was possible that the charge-reversal 
mutations could be destabilizing the structure of Rab5. Therefore, other more modest mutations 
were tested, such as mutation to alanine for many of the amino acids investigated.  
 Rab5 amino acids involved in the binding-site to other Rab5 effectors (i.e. Rab5-GTP 
binding proteins) such as EEA-1, Rabaptin-5 and Rabenosyn-5 may also play a role in p110β 
binding. Therefore, eight additional mutations of Rab5 were chosen for p110β binding 
experiments: I53A, F57A, W74A, Y82A, L85A, M88A, Y89A and R91E; several of which 
were in switch II (AA 77-95). All of these mutants showed some reduction in p110β binding 
(Figure 4.11, 4.12 and Table 4.2). Of these, M88A, Y82A and I53A showed the most reduction 
of p110β binding. Thus, the Rab5 surface required for p110β binding was successfully 
identified (Figure 4.12 B). 
 
Figure 4.10 Residues that may bind p110β on crystal structures of Rab5 in both GDP and 
GNP bound conformations. Residues (blue) selected in the switch regions which have different 
conformations between GDP (1TU4) A, C and GNP(1R2Q) -bound Rab5 structures B, D and are 
facing outwards from Rab5 in the GNP-bound structure. 
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Figure 4.11 Myc3-iSH2-p110β does not Bind to Rab5 switch II region mutants. A. GST, GST-
Rab5 wt and mutant (as indicated) fusion proteins (10 µg) immobilized on glutathione Sepharose 
beads were loaded with either GDP or GppCp and incubated with Myc3-iSH2-p110β from 
transfected COS-1 lysates. Bound Myc3-iSH2-p110β was detected using an immunoblot analysis 
with an anti-Myc antibody. B. Quantification of pull-down binding data from A. Intensity of 
GppCp-bound mutant lanes was measured in arbitrary units and normalized to that of Rab5wt-
GppCp; mean  SD. (*) P<0.01, one way ANOVA (F = 10.96, df = 104), Dunnett’s multiple 
comparison test. Only statistically significant P values are indicated. Also see Figure 4.12 & Table 
4.2 for additional results. 
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Figure 4.12 Rab5 mutations that affect p110β binding. A. Table of Rab5 mutations organized 
by their effect on Myc3-iSH2-p110β binding. Experiments were carried out with different Rab5 
mutant combinations so the number of replicates for each mutant is indicated in brackets.  B. 
Rab5-GNP structure (1R2Q) displaying the mutated amino acids that had little or no effect on 
Myc3-iSH2-p110β binding (black), reduced Myc3-iSH2-p110β binding slightly (green), or greatly 
reduced binding (blue).  
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Mutation 
pull-down Experiment with Myc3-iSH2-p110β 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
S34N - - 
Q44E ++ ++ ++ 
H46A +++ +++ +++ +++ +++ +++ +++ 
E47A + +++ +++ +++ + ++ + 
I53A - - - + - - 
F57A + -/+ - - 
W74A + - + + + 
Q79L - - +/- + + + 
E80R - - - - - - - - 
R81E - - - - +/- 
Y82A - - +/- - 
H83E - - + - - - + - + 
S84A +++ +/- +++ +++ +++ +++ ++ 
L85A - + - - - ++ - - - +/- 
M88A - +/- - - 
Y89A + - + - +/- 
R91E + + + + 
wt +++ ++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ ++ +++ 
Table 4.2 Myc3-iSH2-p110β experiments. Experiments are represented by numbers along the top 
row. Each row depicts the amount of p110 binding in the GppCp bound form of a Rab5 mutant. 
Hierarchy of binding as follows: - (little or no binding), +/- (small amount of binding), + (binding 
observed), ++ and +++ (means substantial binding was observed). Blank spaces mean the mutant 
was not tested in that particular experiment. Arrows indicate the experiments that were represented 
in Figure 4.11.   
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4.6 Identification of Rab5 binding site with the p110β RBD domain 
 Previous studies have shown that p110 has a Ras Binding Domain (RBD: AA 196-286; 
Figure 4.13 A) through which it interacts with the small GTPase Ras. Considering that Rab5 is 
also a small GTPase and has some structural similarity to Ras, it has been proposed that p110β 
binds to Rab5 via the same domain. This theory has been affirmed by deletion mutations of 
p110β followed by pull-down experiments, and has been narrowed down to the Rab5 binding 
site to amino acids 136-270 of p110β (Kurosu and Katada, 2001). To determine the precise 
amino acids involved in Rab5 binding, a structural alignment between the RBDs of p110α 
(which does not bind Rab5-GTP) and p110β was performed with the assistance of Dr. Stanley 
Moore (Figure 4.14).  
 The crystal structure of p110β had been solved in complex with the p85 cSH2 and iSH2 
domains (PDB: 2Y3A) but the p110β amino acids 234 to 240 were disordered (Zhang et al., 
2011). Alignment of the amino acid sequence demonstrated marked divergence between p110β 
RBD consensus sequence (AA 200-260) and that of p110α (Figure 4.13 B). Despite this, the 
residues surrounding the disordered region overlay well in the structural alignment (Figure 
4.14). Five amino acids in the p110β RBD were identified to be distinct in both identity and 
positioning from p110α (in parentheses): L232 (T), I234 (S), E238 (S), D239 (S) and Y244 (G) 
though no conformational information was available for I234, E238 or D239. These amino 
acids were assessed for sequence conservation in p110β from 4 different species, rat, mouse, 
human and cow (Figure 4.13 B). Four of the residues were conserved among all species 
analyzed, while Y244 was conserved in human and bovine sequences only. These five amino 
acids were mutated separately within the full-length Myc-iSH2-p110β protein.  
 Pull-down experiments were performed with wild-type Rab5 in either GDP or GppCp 
bound states (Figure 4.13 C). The p110β mutants D239R and L232A mutants showed Rab5-
GppCp binding comparable to p110βwt. p110β-E238R and -Y244A showed little or no binding 
to any form of Rab5, while p110β-I234A also had reduced binding. These results suggest that 
the Rab5:p110β binding interface contains residues I234, E238 and Y244 but not L232 or D239 
within the RBD of p110β.  
 
Figure 4.13 Identification of the Rab5 binding site within p110β. A. Domain representation of 
p110β and p110α (as indicated). ABD, adaptor binding domain; RBD, Ras Binding Domain; C2; 
helical and kinase domains. B. Sequence alignment of p110β from 4 species and p110α, mouse 
using ClustalW (v1.83). Residues not found in the p110β crystal structure are indicated by a blue 
box. Arrows indicate residues that were chosen for mutation. C. pull-down assay where GST-Rab5 
was loaded with either GDP or GppCp and incubated with each Myc3-iSH2-p110β mutant (as 
indicated) and analyzed as before. Blots are representative of 3 independent binding experiments. 
D. Quantification of pull-down binding data from C; intensity measured in arbitrary units and 
normalized to Myc3-iSH2-p110βwt binding to Rab5GppCp; mean  SD. (*) P<0.01, one way 
ANOVA (F = 44.89, degrees of freedom = 17), Dunnett’s multiple comparison test.  
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Figure 4.14 Structural alignment of p110β-cip85β and p110α-nip85α. (lower) Structural 
alignment of the p110βwt and p110α (H1047R) full length protein crystals containing either the C-
terminal SH2 (cSH2) and iSH2 domains of p85β or the N-terminal SH2 (nSH2) and iSH2 domains 
of p85α, respectively. Structure formatted in PyMOL (V.1.4.1, Schrödinger, LLC). Domains of 
p110 and p85 are indicated by dashed blue boxes. p110β-cip85β (PDB ID: 2Y3A) in dark red and 
dark grey; p110α-nip85α (PDB ID: 3HIZ) in green and silver. (upper) RBD magnified domain with 
mutated amino acids indicated in either red (little or no effect on Rab5 binding) or yellow 
(reduction in Rab5 binding). p110β residues not present in structure are listed to the right.  
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5.0 DISCUSSION 
5.1 Experiments to determine the binding site of p85 on Rab5 
5.1.1 p85 regulation of and binding to Rab5 and Rab4 
 Rab proteins have critical roles in protein trafficking between different intracellular 
compartments including during endocytosis of activated surface receptors. As such, their 
activities are tightly regulated to protect growth factor receptors from undergoing inappropriate 
endocytic trafficking. The GAP p85 is especially relevant to the regulation of receptor 
trafficking dynamics because it inactivates both Rab5 and Rab4 (Chamberlain et al., 2004). 
Rab5 is involved in the movement of activated receptors from early to sorting endosomes by 
regulating the fusion of early endosomes. Rab4 is involved in the recycling pathway of 
intracellular vesicle trafficking where internalized receptors on early/sorting endosomes are 
returned to the plasma membrane. Once recycled, receptors can resume interaction with their 
extracellular ligand, eliciting cellular effects by downstream protein signaling cascades. 
Alternatively, some receptors can be diverted from early/sorting endosomes to lysosomes and 
result in receptor degradation to terminate signaling events. If both Rab5 and Rab4 trafficking 
steps are overactive by disruption of their regulation, receptors could be repeatedly activated 
without proper signal attenuation which requires their degradation. Overactive growth factor 
signaling pathways is a major cause of tumorigenesis (Samuels and Waldman, 2010; Takeuchi 
and Ito, 2011; Bartholomeusz and Ganzalez-Angulo, 2012).  
 The binding between p85 and Rab5 has been investigated previously (Chamberlain et 
al., 2004). It was determined that p85, which had GAP activity towards Rab5, bound to both 
active GTP- and inactive GDP-bound states of Rab5. The binding of p85 to other Rab proteins 
had not been determined, although p85 had GAP activity towards both Rab4 and, to a lesser 
extent, Rab6, but not to Rab11 (Chamberlain et al., 2004). Through pull-down experiments 
with purified Rab proteins Rab5, Rab4 and Rab11 it was investigated whether p85 binding and 
GAP activity were correlated. In section 4.1, it was clearly shown that p85 bound to both Rab5 
and Rab4 in either activation state, but had little or no binding to Rab11. Therefore, the binding 
of p85 was consistent with its GAP activity towards Rab proteins.  
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There were some differences in pull-down experiment results with Rab5 when using 
purified p85 and FLAG-p85 from lysate. It would be expected that the purified p85 protein 
would have increased binding to its substrates over the FLAG-p85 expressed in lysate because 
in lysate other proteins can compete for binding, including endogenous p85, whereas purified 
p85 had little or no contaminating proteins to compete for binding. However, the results of the 
pull-down experiments with Rab4 suggested that purified p85 bound less to Rab4 than FLAG-
p85 from lysate (Figure 4.1). It is possible that the FLAG-p85 expressed in mammalian cells 
was folded in a different conformation that led to more productive binding as compared to 
bacterially expressed and purified p85. Another possibility is that post-translational 
modifications occurring in mammalian cells impacts p85:Rab4 binding. Rab11 had little or no 
binding with FLAG-p85 from lysate. Increased p85 binding to Rab11-GTPγS was observed 
when using purified p85, though it did not bind Rab11-GDP. Mammalian FLAG-p85 
transfected cell lysates were used for subsequent binding experiments to control for differential 
folding in bacterial cells and/or post-translational modifications of p85 that may be important 
for Rab protein binding.   
Rab5 showed good binding to FLAG-p85 in both its GDP and GTPγS bound forms 
(Figure 4.1), consistent with previous observations (Chamberlain et al., 2004). The difference in 
FLAG-p85 binding between Rab5 activation states varied between experiments. In the Rab5, 
Rab4, and Rab11 experiments, FLAG-p85 bound more to Rab5wt-GTPγS than to Rab5wt-GDP 
(Figure 4.1 A, upper) whereas, in the experiments with the mutations of site A and B residues, 
FLAG-p85 bound more to Rab5wt-GDP (Figures 4.4 and 4.5).  
Overall, p85 and FLAG-p85 bound to Rab4 about half as much as to Rab5 (Figure 4.1), 
which suggests that p85 may have a preference to bind Rab5 in the cell, and may exert a 
stronger effect on Rab5 regulation compared to Rab4. However, there are many other factors 
that may influence the p85:Rab4 interaction in vivo, such as proximity of the two proteins or 
competition between Rab5 and Rab4 for binding p85. If GAP activity of p85 is predominantly 
involved in Rab5 regulation, its disruption should have a greater impact on Rab5-mediated 
trafficking of receptors to the early endosome than on Rab4-mediated receptor recycling to the 
plasma membrane. The GAP-deficient p85-R274A mutant was investigated previously 
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(Chamberlain et al., 2004; Chamberlain et al., 2010), but the magnitude of its effect on Rab5 
compared to Rab4 was not measured or apparent. 
5.1.2 Pull-down experiments with FLAG-p85 and Rab5 mutants 
A sequence alignment between Rab4, Rab5 and Rab11 was used to identify residues 
that could be involved in p85 binding (Figure 4.2). Eight residues (S84, E106, N113, F145, 
E172, M175, K179 and K180) were selected based on their conservation in Rab4 and Rab5 and 
divergence in the Rab11 sequence. Pull-down experiments were performed with Rab5 proteins, 
with mutations in the eight chosen amino acids, to test two putative binding sites for p85, 
arbitrarily termed site A and site B.  
In the site A experiments (S84A, E106A, N113A, N113E), there was one mutation of 
Rab5 within the switch II region, e.g. S84A, which reduced binding to p85 in three experiments 
(Figure 4.4). It is still unknown what caused the S84 mutant to have reduced binding to p85, but 
it is known that the protein used in the three experiments were from the same preparation of 
Rab5-S84A. Therefore, additional testing of different preparations of this mutant (as well as 
other mutations of this residue) was deemed sufficient to assess its importance in p85 binding, 
and ultimately eliminate S84 as a candidate involved in the p85:Rab5 binding interface.  
Rab5 mutants bearing substitution within site B, e.g. F145A, E172A, E172R, K179A 
and K180A, had different effects on p85 binding when bound to GDP or GTPγS (Figure 4.5). 
An increase in FLAG-p85 binding could mean that the side chain of the mutated residue is 
normally disruptive to p85:Rab5 binding, or that it constrains Rab5 in a less productive shape 
for p85 binding that the mutation releases. Therefore, it is possible that the Rab5 amino acids 
residing near those whose mutation increased FLAG-p85 binding may be involved in the 
binding site. Mutation of residues next to E172, for example, may decrease p85 binding to 
Rab5. Another possibility is that the binding site of p85 on Rab5 is mainly non-polar and the 
removal of large or charged functional groups, and their replacement with a methyl group (from 
mutation to alanine), would increase affinity of p85 for Rab5 and possibly expand the binding 
site between the proteins. Incongruent with this theory is the fact that a charge reversal caused 
the greatest increase in binding, namely E172R. Interpretation of the data suggests that residues 
in site B of Rab5 are not normally involved in p85 binding, though their mutation may provide 
additional contacts to expand the existing binding site on Rab5.  
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It was decided to perform pull-down binding studies with FLAG-p85 from lysate 
instead of purified p85 protein, although that may not have been the best choice because p110 
(alpha or beta) binding to FLAG-p85, as well as the competition with endogenous p85, may 
have impacted the results. If p110β was bound to FLAG-p85 during the pull-down experiments, 
for example, any Rab5 mutation-induced reduction of p85 binding could have been masked by 
p110β:Rab5 binding – which would artificially increase the FLAG-p85 signal. However, by the 
time this became apparent, most of the experiments had already been completed. 
5.1.3 Rab5 binding to p85 using yeast two-hybrid experiments 
The mutation of carefully selected amino acids did not resolve the p85 binding site on 
Rab5, so yeast two-hybrid experiments were pursued as a non-biased method to identify Rab5 
amino acids involved in binding to p85. Yeast two-hybrid experiments are useful to identify 
binding partners of a bait protein from a large library of prey proteins. With the use of replica 
plating and plasmid DNA sequencing, one can also screen for non-binding proteins based on 
the lack of growth in selection media as compared to a positive control. A library of B42-Rab5 
proteins randomly mutated by an error-prone DNA polymerase was to be tested for binding 
with p85. Non-binding mutant expressing colonies would not grow in selection media and 
would be traced back to the original plate and sequenced.  
The yeast two-hybrid experiment with wild type Rab5 and p85, however, was not 
successful. Though both proteins were expressed in the diploid yeast colonies in galactose 
media (data not shown), it seemed that their interaction was not strong enough, or perhaps not 
stable enough, to drive the transcription of the reporter genes. It is possible that, by growing the 
yeast on media lacking both adenine and leucine, as well as containing X-gal, the stringency for 
interaction was too high. Perhaps if each of the markers were selected for separately, first 
looking for adenine gene expression, then leucine, it would have been less stressful for the 
yeast.  
Another possible difficulty with the yeast two-hybrid experiments might have been the 
structure of the fusion proteins. Both Rab5 and p85 were expressed in yeast as B42 and Lex-A 
fusion proteins, respectively, attached at the N-terminus of the protein of interest. The folding 
of the fusion proteins may have masked the binding site of either Rab5 or p85, resulting in their 
inability to bind each other. One way to assess the effects of folding on the ability of the fusion 
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proteins to interact would be to reverse the order of proteins expressed, so that Lex-A or B42 
are expressed as the second protein attached C-terminally to p85 and Rab5, respectively. The 
B42 protein has a nuclear localization signal that would also have to remain at the N-terminus. 
While being tethered to other proteins, the freedom of movement in space of Rab5 and p85 was 
restricted, and may have been the reason that they did not interact in the yeast two-hybrid 
experiments.  
5.1.4 The p85 binding site on Rab5: other possibilities and future studies 
The original hypothesis of the p85 binding experiments hinged on the fact that p85 
bound to all conformations of Rab5. This result suggested that residues involved in binding 
would be positioned similarly and available for binding in both active and inactive forms, so 
binding should not be conformation dependent. However, this hypothesis was reconsidered 
after testing mutations of Rab5 amino acids with conserved orientation between active and 
inactive states for p85 binding, which did not resolve the binding site on Rab5. It is possible 
that the Rab5 residues involved in p85 binding could differ between activation states and that 
two binding sites could exist on Rab5 that both bind p85. This project did not determine the 
binding site of p85 on Rab5.  
The p85 mutant R274A does not bind to Rab5-GTP, suggesting that the arginine residue 
may be critical for Rab5 interaction (Chamberlain et al., 2004). As mentioned in section 1.5, an 
arginine finger generally forms H-bonds with the conserved glutamine (Q79) through its 
backbone carbonyl group and H-bonds with the γ-phosphate or β-γ bridge oxygen of GTP 
through the guanidinium group (see Figure 1.9). Mutation of this arginine to alanine would not 
disrupt the backbone interactions unless the position of the residue was shifted, which is 
possible. Conversely, the mutant p85-R274A still bound to Rab5-GDP. To further complicate 
matters, the BH-domain deletion mutant of p85 bound to Rab5-GTP but not Rab5-GDP 
(Chamberlain et al., 2004) which suggests that other region(s) of p85 outside the BH domain 
help to bind Rab5. Interpretation of these findings is difficult, but it does suggest that the 
different conformations of Rab5 could be interacting with p85 in different ways, and possibly 
for different purposes. 
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5.1.4.1 p85 could be a GDF to Rab5 
Generally, Rab5-GDP is cytosolic, bound to a GDI which makes contacts with both 
switch regions and the geranylgeranylated C-terminus (Figure 1.5 and 5.1 B). The mechanism 
of recruitment of Rab proteins to their target membranes remains controversial. Some research 
shows that nucleotide exchange is sufficient to release the tightly bound GDI from a Rab 
protein, as its affinity for the active conformation of Rab GTPases is very low (Wu et al., 2010). 
Another study demonstrated that post-translational modification of the Rab, as well as direct 
competition by other Rab binding proteins, was effective in GDI displacement (Oesterlin et al., 
2012). However, for a GEF to stimulate guanine nucleotide exchange or for the Rab to be 
modified by enzymes (i.e. phosphocholination by AnkX), the GDI must be displaced, because 
GDI, GEF and AnkX interact with a similar epitope on the GTPase (Wu et al., 2010; Oesterlin 
et al., 2012). Thus, GDI displacement factors (GDFs) have been assumed to fill the role for 
GDI displacement at the target membrane.  
One family of GDFs, the Ypt interacting proteins (Yip)s, has been discovered in yeast. 
Yip3 and its human homologue prenylated Rab acceptor-1 (PRA-1) were found to induce 
dissociation of Rab9 from Rab9-GDI complexes (Sivars et al., 2003). PRA-1 may facilitate 
GDI release in a non-specific manner because it interacts with many prenylated Rab proteins in 
mammalian cells (Bucci et al., 1999; Martincic et al., 1997). The mode of action of GDI 
displacement by Yips is not fully understood, though it is hypothesized that the Rab C-terminal 
isoprenyl groups are transferred from the GDI to the GDF (Pfeffer and Aivazian, 2004).  
It has been suggested in the literature that p85 could be involved in recruiting Rab5 to 
the plasma membrane, acting as a GDF on the inactive Rab5-GDP (Chamberlain et al., 2010; 
Mellor et al., 2012). From the binding data available, it is unclear whether p85 binds to Rab5-
GDP in the cellular environment. Pull-down data in this thesis and previously reported 
(Chamberlain et al., 2004) made use of purified Rab proteins loaded with the guanine 
nucleotide of choice, therefore the complication of GDI binding was not tested. If p85 did bind  
Rab5-GDP in vivo, it would need to displace the GDI or bind to a region of Rab5 which is not 
involved in binding GDI. Fluorescence resonance energy transfer (FRET) experiments using 
fluorophore-tagged Rab5 and p85 could be used to characterize their interaction in vivo. 
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Moreover, the use of dominant-negative (S34N) and GTP-locked (Q79L) mutants of Rab5 in 
the FRET analysis would clarify whether p85 binds to Rab5-GDP in vivo.  
One region of Rab5 that was not investigated for p85 binding was the C-terminal 
hypervariable region (AA 186-215; Figure 5.1) because it was not included in the Rab5-GDP or 
Rab5-GNP crystal structures and it had been found previously to not be involved in effector 
binding (Zhu et al., 2007). This region is predicted, by comparison with the solved structure of 
the Ypt1:GDI complex, to bind loosely to the GDI protein via conserved hydrophobic residues 
V199 and L201 and the two gernanylgeranyl groups attached to C212 and C213, which are 
bound in a separate hydrophobic compartment of GDI (Rak et al., 2003; Pfeffer, 2005; Figure 
5.1 A). The loose attachment of the hypervariable region to GDI may present AA 181-198 and 
202-211 on the outside face of the Rab5-GDI complex (Figure 5.1 B), as seen in the Ypt1:GDI 
complex (Rak et al., 2003). If that is the case, the residues would be available for binding with 
other proteins such as p85. If p85 binding to Rab5-GDP was confirmed in vivo, for example by 
a co-immunoprecipitation (and immunoblotting with both anti-Rab5 antibody and anti-active 
Rab5 antibody, which detects only Rab5-GTP, as a control) or by FRET, the hypervariable C 
terminus would be a good target for mutagenic binding studies to continue the search for the 
p85 binding site on Rab5.   
There were other amino acids which were identified in the sequence alignment that were 
conserved in Rab5 and Rab4 but not Rab11, but were not investigated because they were not 
included in the crystal structure of Rab5 (1TU4 and 1R2Q). These amino acids were N10, T14, 
G190, G197, G199, and A214. Without knowledge of how these residues are positioned in the 
tertiary structure of Rab5 it cannot be known whether they are available for p85 interaction. 
Because the p85 binding site on Rab5 was not determined in this thesis, these amino acids are 
good candidates for mutation and testing based on the original hypothesis.  
 
Figure 5.1 Sequence of Rab5 C-terminal hypervariable region. A. Representation of the amino 
acid sequence present in the crystal structure of Rab5 (PDB ID: 1R2Q, 1TU4) in relation to the N- 
and C-terminal hypervariable regions. B. Sequence of the C-terminal hypervariable region. Valine 
199 and leucine 201 interact with a hydrophobic domain of GDI (dashed lines). Conserved 
cysteines 212 and 213 interact with GDI via post-translationally added geranylgeranyl groups. 
Arrows indicate residues which are conserved between Rab5 and Rab4 but not Rab11 amino acid 
sequence, and therefore may be involved in p85 binding.  
N-terminal 
hypervariable 
region 
(AA 1-14)  
C-terminal 
hypervariable 
region 
(AA 186-215)  
Crystal structure (AA 15-185) 
        190                  199  201                 210 
…PQNPGAHSARGPGVDLTEPAQPARSQCCSN 
N- -C 
 
 
GDI 
 
 
g
eran
y
lg
eran
y
l 
g
eran
y
lg
eran
y
l 
Rab5 
A 
B 
79 
80 
 
5.1.4.2 p85 binding to Rab5 could be activation-state dependent 
To determine how a small GTPase normally interacts with its GAP, a structural 
alignment of Rab5-GNP (1R2Q) with the small GTPase Cdc42 (1AM4), of the Rho subfamily, 
was performed (Figure 5.2 A). The crystals showed good structural similarity. Cdc42 has been 
co-crystallized with its GAP, p50rhoGAP (“rhoGAP”), and therefore the residues involved in 
polar interactions between them could be determined (Rittinger et al., 1997a). The structural 
alignment identified Rab5 amino acids that corresponded to residues of Cdc42 which made 
polar contacts with rhoGAP, which could be tested for effect on p85 binding, including: S29, 
F57, R81, and Y82 (Figure 5.2 B). Of these residues, F57, R81, and Y82 were found to be 
involved in p110β binding of Rab5 (discussed in greater detail below) and thus would not be 
available for binding to p85. The orientation of serine 29 does not change between activation 
states.   
As a comparison, another structural alignment was performed with Rab5-GNP (1R2Q) 
and Rho (1TX4), which was also co-crystallized with rhoGAP (Rittinger et al., 1997b; Figure 
5.2 C). Again, the same four residues in positions equivalent to Rab5 S29, F57, R81 and Y82 
were found to be involved in polar contacts with the GAP (Figure 5.2 E). However, in this 
second alignment, there was a second set of polar contacts including Rab5 equivalent residues 
E106, R110, and N113 (Figure 5.2 D). Both E106 and N113 were mutated and investigated in 
the site A pull-down experiments (Figure 4.4) and their mutation did not affect p85 binding. 
Therefore, from the two structural alignments with Rho-family proteins, Cdc42 and Rho, the 
only new candidate amino acids for p85 binding to Rab5 that have not been pursued, or are not 
already involved in p110β binding, were S29 and R110. The side chain of arginine 110 points 
outwards in the Rab5-GDP crystal structure and folds inwards in the active Rab5-GNP crystal, 
so its involvement in p85 binding would make the interaction conformation dependent. Some 
Rab5 mutations, i.e. F145A, E172R, K179A and K180A, had different effects on p85 binding 
when in the GDP- vs. GTP-bound conformation, which also supports the activation-state 
dependence of p85 binding to Rab5. 
The crystal structure of the p85 BH domain has also been determined (Musacchio et al., 
1996). Alignment of rhoGAP (1AM4) and p85BH (1PBW) has been described previously 
(Fidyk and Cerione, 2002). In their study, attention was paid to the lack of switch stabilizing  
Figure 5.2 Structural alignment of Rho protein/GAP complexes with Rab5-GNP and p85 BH 
domain.  A. Cdc42 (red) co-crystallized with p50rhoGAP (brown) (PBD ID: 1AM4) was aligned 
with Rab5-GNP (teal, 1R2Q) and the BH domain of p85 (blue, 1PBW) using PyMOL. GNP in 
black; yellow dashes indicate polar contacts between Cdc42 and p50rhoGAP. B. Close up view of 
the interaction interface. Rab5 amino acids (teal) in equivalent positions to those of Cdc42 involved 
in polar contacts with p50rhoGAP are numbered. p85-R151 in blue, p50rhoGAP-R85 in brown. C. 
Rho (orange) co-crystallized with p50rhoGAP (purple) (PDB ID: 1TX4) was aligned with Rab5-
GNP (teal) and the BH domain of p85 (blue) as in A.  D. Close up of polar contacts between Rho 
and p50rhoGAP that are not seen in Cdc42:p50rhoGAP interaction. Equivalent amino acids  of 
Rab5 are indicated. E. Same as B, but for the Rho/Rab5, p50rhoGAP/p85BH alignment.  
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contacts available on the p85 structure. However, the catalytic arginine finger R274 was 
pointing inwards in the alignment with rhoGAP crystal 1AM4 (Figure 5.3 A) as well as when 
aligned with the structure of p120rasGAP, 1WQ1 (Figure 5.3 B). Another arginine of 
p85,R151, aligned well with the arginine finger of rhoGAP, R85 (Figure 5.3 C) and that of 
p120rasGAP, R789 (Figure 5.3 D). Since mutation of R151 scarcely affected p85 GAP activity 
while mutation of R274 greatly reduced GAP activity (Chamberlain et al., 2004), it has already 
been established that the arginine finger of p85 is R274. Thus, if R274 is facing inwards in the 
alignment with rhoGAP and p120rasGAP, the alignment may not accurately portray the method 
of action of p85 GAP activity and its interaction with Rab5. 
5.2 Experiments to determine the p110β binding site on Rab5 
5.2.1 Myc3-iSH2-p110 does not co-immunoprecipitate with p85 
 Phosphatidylinositol 3`kinase is an obligate heterodimer (Hirsch et al., 2007).  The class 
IA isoforms, which are the focus of this thesis, require interaction of p110 and p85/p55 subunits 
for stability (Klippel et al., 1993). Thus, the generation of a p110β protein source which did not 
bind p85 in vivo was necessary to isolate the binding event between Rab5 and p110β. Using the 
template of LT Williams’ lab (Hu et al., 1995), a chimeric protein was generated which 
encoded the iSH2 domain of p85 attached N-terminally to the full-length p110 protein by a 
glycine linker (Figure 4.7 A). This protein was readily detected in transfected COS-1 cell 
lysates through its triple Myc tag using anti-Myc antibodies (Figure 4.8). As predicted, the 
iSH2 domain containing p110 proteins showed little or no binding to either FLAG-p85 or 
endogenous p85 in a co-immunoprecipitation assay (Figure 4.8 B and D). The iSH2 domain of 
the chimera would be able to bind to the ABD of p110, thus stabilizing the chimeric p110 
protein as well as saturating a major contact point between p110 and p85, precluding the 
binding of full-length p85 to that site. While the iSH2 domain was able to stabilize p110, it 
would not be able to provide inhibitory contacts to the helical or kinase domain of p110 since 
these are provided by other regions of p85. Therefore, the Myc3-iSH2-p110 protein would be 
expected to be constitutively active, as it was for LT Williams (Hu et al., 1995). The lipid 
kinase activity of the chimera generated in this thesis was not tested. The isolation of p110 from 
p85 binding was the sole purpose of the chimera to be used in pull-down experiments with 
Rab5.  
R151 R85 
R274 
R274 
Figure 5.3 Arginine finger orientation from structural alignment of the p85 BH domain with 
p50rhoGAP and p120rasGAP. A. Structural alignment between p85 BH domain (PDB ID: 
1PBW, blue) and p50rhoGAP (1AM4, brown). Close up of the arginine finger of  p85, R274. B. 
Structural alignment between p85 BH domain (1PBW, blue) and p120rasGAP (1WQ1, green). 
Close up of p85-R274. C. Alignment as in A. Close up of p85-R151, which aligns with the arginine 
finger of p50RhoGAP, R85. D. Alignment as in B. Close up of p85-R151, which aligns with the 
arginine finger of p120rasGAP, R789. 
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5.2.2 Pull-down experiments with Myc3-iSH2-p110β and Rab5 mutants in the switch 
regions  
 In 1999, Christoforidis and colleagues demonstrated that the p110β isoform only binds 
to active Rab5 by affinity chromatography (Christoforidis et al., 1999). Therefore it was 
hypothesized that the residues of Rab5 involved in binding p110β were within the switch 
regions of the protein and that the interaction was conformation dependent. Therefore, the 
iSH2/p110 chimera was used in pull-down binding experiments to identify Rab5 mutants that 
reduced binding to p110, without the complication of p85 binding. The p110 binding to wild-
type Rab5 correlated well with published results: Myc3-iSH2-p110β only bound to Rab5wt-
GTP (Figure 4.9). As expected, Myc3-iSH2-p110α did not bind Rab5 in either activation state 
(Figure 4.9). 
Mutations of amino acids in switch I and switch II regions of Rab5 were then tested for 
binding to Myc3-iSH2-p110β. Some Rab5 mutants had variability in p110β binding which was 
not ideal. Most Rab5-GDP lanes have a trace amount of p110β binding, which could be 
attributed to the incomplete stripping/loading of Rab5 with the nucleotide of choice, as 
previously shown by Cody Bergman in his thesis (Bergman, 2012). Therefore there could be 
some residual Rab5-GTP on the glutathione-Sepharose beads after nucleotide exchange, and 
therefore a potential binding partner for small amounts of p110β.  
 Mutations of Rab5 that reduced p110β binding were I53A, F57A, W74A, Q79L, E80R, 
R81E, Y82A, H83E, L85A, M88A, Y89A and R91E which are depicted as a binding site on the 
Rab5 protein crystal structure in Figure 4.12. Interestingly, S84A did not affect binding despite 
its location in the center of the binding site. The hydroxyl group of S84 may not make polar 
contacts with p110β, but the backbone of the protein might still be involved in binding and 
would not have been affected by its mutation to alanine. Most of the residues mutated which 
reduced p110β binding reside in the switch II region of Rab5, whereas the only mutation in 
switch I that reduced binding was E47A, and it only had a small effect compared to the other 
mutations. Three residues from the “inter-switch” region (or the sequence between the switch I 
and switch II regions i.e. AA 53-77) were also involved in the binding interface: I53, F57, and 
W74. Looking at the crystal structures of Rab5 (Figure 4.3 A vs. B), switch I (purple) adopts a 
greater difference between activation states than does switch II (red), therefore its stabilization 
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should make the greater difference in activation energy required for the reaction. A 
possible reason for the greater representation of switch II in the p110β binding site is the 
structural variability in the switch II region due to non-conservative substitutions between Rab 
proteins, while the inter-switch and switch I regions derive specificity in binding by their 
conformation which is indirectly influenced by packing of secondary structure within the 
protein core (Mishra et al., 2010).  
5.2.3 The binding site of p110β on Rab5 
It is possible that there are more Rab5 residues involved in binding p110β which were 
not identified in this thesis. Other Rab5 amino acids in the switch II region, i.e. A86 and Y90 
were not tested but could make contacts with p110β, as well as amino acids proximal to I53: 
G54, A55, and A56, which were involved in binding other effectors, Rabenosyn-5 and EEA-1 
(Mishra et al., 2010; Eathiraj et al., 2005). The data available for Rab5 effector binding sites, 
including EEA1, Rabenosyn-5, Rabaptin-5 and APPL1, was summarized in Table 5.1 and 
compared to the results of binding studies with p110β.  
Co-crystal structures including Rab5 and effector were used to determine residues 
involved in binding to EEA1 (Mishra et al., 2010) and Rabaptin-5 (Zhu et al., 2004), whereas 
the binding site for APPL1 (Zhu et al., 2007) and Rabenosyn-5 (Eathiraj et al., 2005) were 
inferred from crystal structures not containing Rab5 and mutational binding assays, as was done 
with p110β in this thesis. Both EEA1 and Rabenosyn5 bound Rab5 via a FYVE zinc-finger 
motif. Rab5 bound to the PH domain of APPL1 in the context of APPL1 BAR-domain:PH-
domain dimers. Similarly, Rab5 interacted with the coiled-coil C-terminal domains of Rabaptin-
5 dimers. The RBD of p110β was demonstrated previously (Kurosu and Katada, 2001) to be the 
binding site for Rab5.  
The binding site of p110β on Rab5 included a majority of residues also involved in 
binding Rab5 effectors (Table 5.1). The need for a unique binding epitope to ensure specificity 
of effector recruitment and binding became apparent when the extensive structural and 
sequence homology between other members of the Ras superfamily of small GTPases and Rab5 
was considered. Positioning of functional groups is important for effector recognition of their 
Rab binding partner. Amino acids F57, W74 and Y89, for example, are called the invariant 
hydrophobic triad (Merithew et al., 2001; Table 5.1, highlighted in orange), because they show  
Amino acid 
involved in 
binding (Y/N) 
Rabenosyn-5 
(Rab22 crystal 
structure & mut 
binding) 
EEA-1 
(crystal structure) 
Rabaptin-5 
(crystal structure 
& mut binding) 
APPL1 
(mut binding) 
p110beta 
(mut binding) 
Q20 Y N N - - 
K22 N Y N - - 
L38 N N N N - 
K42 Y N N Y - 
Q44 N N N Y N 
H46 N N N Y N 
E47 N N N - Y/N 
F48 N N N Y - 
Q49 N Y N N - 
E50 Y/N Y N N - 
S51 Y Y N - - 
T52 N Y N - - 
I53 Y Y N N Y 
G54 Y Y Y - - 
A55 Y/N Y Y - - 
A56 Y Y N - - 
F57 Y Y Y N Y 
L58 N N Y - - 
T59 Y/N N Y - - 
Q60 N N N  -  - 
K70 Y N N - - 
E72 Y/N Y N - - 
W74 Y Y Y Y Y 
Q79 N N N Y Y 
E80 N N N - Y 
R81 Y N Y - Y 
Y82 Y Y Y - Y 
H83 N N N - Y 
S84 Y Y N - N 
L85 Y Y Y Y Y 
P87 N N N - - 
M88 Y  Y Y Y Y 
Y89 Y Y Y Y Y 
R91 Y Y N - Y 
Table 5.1 Rab5 amino acids involved in binding effectors. Rab5 amino acids involved in binding 
with at least one of 5 effectors: Rabenosyn-5 (Eathiraj et al., 2005), EEA-1 (Mishra et al., 2010), 
Rabaptin-5 (Zhu et al., 2004), APPL1 (Zhu et al., 2007) and p110β (this thesis) are indicated in the 
left column. If mutation of the amino acid (mut binding) affected binding to the effector or if the 
crystal structure revealed a contact point with that amino acid, a Y signifies “yes” or important for 
binding. If the mutation did not affect binding, or the crystal structure showed no interaction with 
that amino acid, a N depicts “no” or not important for binding. Y/N means both positive and 
negative results have been demonstrated. “-” means the amino acid has not been tested for binding. 
The invariant hydrophobic triad amino acids are highlighted in orange. Unique amino acids of Rab 
phylogenic group 5 are highlighted in green. Amino acids which were important for binding all 
effectors tested and are not included in the groups above are highlighted in light purple. Amino 
acids specific to binding p110β are highlighted in blue. 
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drastic conformation differences between Rab proteins while still being highly conserved in all 
Rab protein sequences. These three residues have been implicated in Rab5 binding with 
effectors EEA-1, Rabenosyn-5, Rabaptin-5, APPL1 and now p110β.  
Rab5 is a member of phylogenic group 5 of Rab GTPases, which also includes Rab21 
and Rab22 (Pereira-Leal and Seabra, 2001). Both A56 and M88 (Rab5 AA numbering) are 
unique residues to this phylogenic group and are substituted with non-conservative residues in 
other groups; e.g. A56 is substituted with aspartate in Rab4 (group 2), while M88 is substituted 
with serine in Rab1 (group 1), Rab2 and Rab4 (group 2) and Rab6 (group 6) and with alanine in 
Rab3 (group 3) (Zahraoui et al., 1989). All effectors mentioned in Table 5.1 bound a similar 
Rab5 epitope including the hydrophobic triad, the unique residue M88 of phylogenic group 5 as 
well as L85. Alanine 56 was not mutated and tested for binding with either APPL1 or p110β, 
and therefore, it is unknown if this residue is as important to group 5 binding to effectors as 
M88.  
 Rab5 residues unique to binding p110β were E80 and H83. These residues were mutated 
to a residue of opposite charge, and therefore their effect on p110β binding was substantial. In 
the wild-type Rab5-GNP crystal structure (1R2Q) H83 forms a hydrogen bond with E117 on α-
helix #3 of Rab5 (Figure 5.4 D), so it is possible that the H83E mutation could be destabilizing 
to the Rab5 switch II loop because of charge repulsion between it and E117, causing 
displacement of many residues. Therefore, it is unknown if H83 makes contacts with p110β that 
are disrupted in the H83E mutant or if the mutation caused a large conformational change in 
Rab5 which reduced binding of p110β. Similarly, though E80 does not make intrachain 
contacts with its functional group, substitution of this residue to arginine may cause some 
charge repulsion from Rab5 residue R110, which is also positioned on α-helix 3 and very near 
to E80 in the crystal structure (Figure 5.4 D). Therefore it is unclear whether these amino acids 
are involved directly in p110β binding, or if their mutation distorted Rab5 folding to negatively 
impact p110β binding.  
APPL1 binding to Y82 was not tested (Zhu et al., 2007), but all other effectors bound 
this residue (Eathiraj et al., 2005; Zhu et al., 2004; Mishra et al., 2010; Figure 4.12). Another 
residue which was not tested in APPL1 or in p110β binding studies was G54 which bound to all  
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binding interfaces. A. Structural alignment overlay of the Ras:p110γ complex (1HE8) with Rab5 
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other effectors mentioned. Therefore, some residues which may also be involved in binding 
p110β are G54 and A56. Though the role of glycine in p110β binding would likely rely on 
backbone interactions or through facilitating tight turns in Rab5 secondary structure, mutation 
of these residues to an amino acid with a bulky or charged functional group may disrupt binding 
by steric hindrance or charge repulsion, respectively.  
One consideration of all the Rab5 mutants that reduced binding to p110β is their ability 
to properly bind nucleotide, which was not tested in this thesis. Whenever a protein is mutated, 
its functionality is put to question. Because many of the amino acids were mutated in an 
important catalytic region of Rab5, it is important to test whether the protein can still function. 
Binding of GTP and its hydrolysis is critical for the function of GTPases, and can be tested by a 
few methods: one is an antibody which is specific for a Rab5 epitope only present on GTP-
bound Rab5; another is the binding of radioactive [α-32P]-labeled nucleotide which can be 
detected by autoradiography. Either of these assays should be performed with the Rab5 mutants 
that do not bind p110β before further study or evaluation of these proteins is explored. 
5.3 Experiments to determine the Rab5 binding site on p110β 
5.3.1 The binding site of Rab5 on p110β 
 A sequence alignment between p110α and p110β demonstrated the difference between 
the two isoforms in the RBD (Figure 4.14). When the two structures were aligned, it was noted 
that a loop at the “top” of the RBD as in Figure 4.14 was missing from the crystallized protein, 
because of disorder (Zhang et al., 2011). This loop seemed a promising site for binding, as it 
varied greatly between p110α and p110β, and would be flexible to interact with the switch 
regions of Rab5. Therefore, residues within this loop, as well as some residues around it, were 
mutated in the context of the Myc3-iSH2-p110β protein, and tested for binding with Rab5. It 
was found that some, but not all of the residues tested, were important for binding Rab5. 
Specifically, E238R and Y244A had the largest reduction of binding to Rab5-GppCp, whereas 
I234A reduced binding to Rab5-GppCp by about 70% (Figure 4.13 C and D).  Residues that did 
not affect binding to Rab5 were D239R and L232A, despite their proximity to E238 and I234, 
respectively. There may be additional residues involved in the binding interface, but no other 
residues were mutated at this time.  
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A structural alignment of the Rab5-GNP (1R2Q) crystal with a co-crystal structure of 
Ras-p110γ (1HE8) suggested a different binding motif between the family members (Figure 
5.4). Ras engaged residues including Q24, E37, S39, Y40 and R41 for the interaction with 
p110γ (Figure 5.4 B), while pull-down results demonstrated that Rab5 used residues in the 
switch II region (AA 77-95) to bind p110β (Figure 4.11 and Figure 5.4 C). In a p110β structural 
alignment with p110γ, the (p110β) Rab5-binding residue Y244 faces away from the Rab5 
switch II region (Figure 5.4 C) while residues I234 and E238 of p110β were in the disordered 
region of the p110β crystal. Therefore, though p110β bound Rab5 via its RBD, the interaction 
mechanism is different from p110γ binding to Ras.  
The p110β binding site on Rab5 shares many residues with effectors and GAP proteins 
alike. Therefore, it is important to determine whether p110β is in fact a regulator of Rab5 or an 
effector. Because of the GAP activity of p85, it was expected that p110β may be involved in 
Rab5 deactivation by virtue of being bound to p85. However, the catalytic activity of p110β 
provides PtdIns-3,4,5-P3, an important precursor in the generation of the PtdIns-3-P on early 
endosomes, making it an effector of Rab5 (Shin et al., 2005). It was proposed that p110β 
engages the switch regions of Rab5 in order to stabilize the transition state and drive the 
hydrolysis of GTP. The binding sites between Rab5 and p110β have been identified and 
involved mainly residues from switch II of Rab5. It is unknown if the p110β-RBD:Rab5-switch 
II contacts stabilize the transition state of Rab5. A GAP assay, whereby [α-32P]-GTP hydrolysis 
is measured by thin layer chromatography and autoradiography, would need to be performed 
with p85 added to Rab5 alone, or in the presence of p110β, in order to establish the effect of 
p110β on p85 GAP activity towards Rab5. Since p110β is difficult to purify because of its 
instability without bound p85 and the iSH2-domain containing p110β construct does not 
express well in bacterial cells this assay has not been pursued. Another way to determine if 
p110β stabilizes the transition state of Rab5 would be to crystallize the complex of Rab5-GDP-
AlF4 (a transition state analogue), p85 and p110.  
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5.4 Future studies, overall effects of the non-binding mutants of both Rab5 and p110β 
In this thesis, the p110β binding site on Rab5 was determined. The overlap of critical 
residues with those involved in binding other Rab5 effectors supports the theory of temporal 
regulation of Rab5. If both regulatory and effector proteins bind a similar epitope on the Rab5 
structure, they would be in competition with each other for binding. In the working model, 
membrane bound Rab5-GDP is activated initially by a GEF, e.g. Rin-1, in response to growth 
factor signaling and becomes involved in internalization of activated receptors (Figure 5.5 B). 
 Interaction of active Rab5 with phosphatidylinositol 3′-kinases such as Vps34 and 
p110β, and phosphatases PtdIns-4-phosphatase and PtdIns-5-phosphatase should occur first to 
promote lipid identity and uncoating of the internalized vesicles (Figure 5.5 C). Tethering 
factors such as effectors EEA-1 and Rabenosyn-5 bind to both Rab5-GTP and PtdIns-3-P 
within the vesicle membranes and therefore would be recruited after the lipid kinases and 
phosphatases, when a sufficient level of PtdIns3P is achieved (Figure 5.5 D). Homotypic fusion 
of vesicles and heterotypic fusion of vesicles to the larger early/sorting endosome occur through 
the actions of tethering factors and their recruited SNARE proteins (not shown in the diagram).  
During these steps of intracellular trafficking, Rab5-GTP has been bound to multiple 
effectors, sequestering its switch regions from regulatory proteins. But, once fusion is complete, 
Rab5 effectors are no longer needed and may be released from the early/sorting endosome. 
Rab5-GTP becomes available to GAPs and can be deactivated by GTP hydrolysis and removed 
from the membrane by GDI (Figure 5.5 E). It may be possible that GAPs are acting on Rab5 
throughout the cycle, but GEFs (e.g. Rabex-5) reactivate Rab5 in a positive feedback loop 
designed to ensure Rab5 remains activated until vesicle fusion is completed (Figure 5.5 F). 
Therefore, by interacting with the same site on Rab5 (the switch I and II regions) effectors and 
regulators must compete for binding, resulting in a time-dependent sequential interaction 
pathway.  
 The importance of the Rab5:p110β interaction in cells can be tested by introducing non-
binding mutants of either protein and evaluating the differences in endocytosis, intracellular 
receptor trafficking, as well as downstream RTK signaling compared to wild-type cells. 
However, evaluation of Rab5 mutants unable to bind p110β would be complicated by the 
consequences of other Rab5 effectors being unable to bind the Rab5 mutants, as many of their 
Figure 5.5 Temporal regulation of Rab5 endosomal trafficking. A. Inactive Rab5-GDP is bound 
to GDI in the cytosol. B. Rab5 is activated by a GEF at the plasma membrane. C. Active Rab5 
interacts with phosphatidylinositol kinases and phosphatases. D.  When the PtdIns3P concentration 
is optimal, tethering factors bind both Rab5 and PtdIns3P, and promote vesicle fusion. E. GAPs 
enhance GTP hydrolysis and return Rab5 to an inactive form, to which GDI binds and brings into 
the cytosol. F. GAPs acting on Rab5-GTP on endosomes which have not undergone fusion. The 
resulting Rab5-GDP is reactivated by a GEF in a positive feedback loop that promotes vesicle 
fusion. 
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binding sites on Rab5 overlap. It may be possible to selectively block p110β binding through 
the mutation of Rab5 residues specific for p110β binding, such as E80 and H83, but if their 
mutation affects the overall fold of the switch regions of Rab5, as predicted, there would be 
disruption of all Rab5 effector binding. Thus, it would be more effective and less confusing, if 
the p110β mutants unable to bind Rab5, E238R and Y244A, were introduced into cells instead. 
This may require knock-down of endogenous p110β by si-RNA followed by re-expression of 
an si-RNA insensitive p110β mutant in order to see the full effect of the mutations. When 
p110β was lost or limiting, transferrin receptor internalization (Jia et al., 2008) and EGFR 
internalization (Ciarolo et al., 2008) was impaired, but was restored by expression of a kinase-
dead mutant of p110β. Theoretically, it was the lack of p110β:Rab5 interaction that caused this 
phenotype. Analysis of both transferrin receptor and EGFR internalization should be pursued in 
the p110β-E238R and -Y244A mutant expressing cells. Also, if p110β is stabilizing the switch 
regions of Rab5 during p85-mediated GTP hydrolysis, non-binding mutants E238R and Y244A 
may result in increased active Rab5 in cells, leading to enlarged early endosomes or a similar 
phenotype to p85-R274A expressing cells. Therefore, expression of Rab5-S34N should reverse 
the phenotype as it did in p85-R274A cells (Chamberlain et al., 2008).  
  The mechanism of PI3K regulation of Rab5 is not yet fully understood. As a protein 
whose gene is often mutated in cancer, the function of wild-type p85α is of great interest 
(Samuels and Waldman, 2010; Cheung et al., 2011; Sun et al., 2010). The GAP function of p85 
(Chamberlain et al., 2004) theoretically limits the time and/or amount of homotypic early 
endosomal fusion by deactivation of Rab5 and therefore affects the proper trafficking of 
activated receptors (Chamberlain et al., 2008). The ability of p85 to bind Rab5-GDP, and its 
significance, remains to be tested in vivo. The interaction between p110β and Rab5-GTP may 
be important for the generation of the lipid product PtdIns-3,4,5-P3 on early endosomes, though 
p110β is recruited by the pY residues of RTKs through the p85 SH2 domain interactions and 
not by Rab-GTP. A non-catalytic function of p110β (Jia et al., 2008; Ciarolo et al., 2008) may 
be the p110β:Rab5-GTP switch region stabilization which is important for inactivation of Rab5 
and early endosome development. This thesis has identified residues on both Rab5 and p110β 
which are involved in their interaction. The importance of the Rab5-GTP: p110β interaction 
may be elucidated through the characterization of these non-binding mutants in cells.  
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